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This project stems from the results of a whole exome sequencing analysis of a rare case with a 
progressive, KIT mutation-negative form of advanced systemic mastocytosis (SM) termed mast cell 
leukemia (MCL), that identified biallelic inactivating mutations of the SETD2 gene. SETD2 encodes 
a histone methyltransferase responsible for trimethylation of histone H3 at lysine 36 (H3K36) and 
is a tumor suppressor whose loss of function is implicated in solid tumors and acute leukemias, but 
previously unreported in SM. We thus moved to investigate 1) the prevalence, the underlying 
mechanisms, the pathogenetic role and the ‘druggability’ of SETD2 loss of function in SM, and 2) 
its clinical relevance. Screening of a validation cohort of 57 patients with various forms of SM for 
H3K36 trimethylation levels as a surrogate marker for SETD2 loss of function by Western Blotting 
showed that H3K36 trimethylation is reduced or absent in all cases with SM. Median SETD2 and 
H3K36 trimethylation levels resulted to be significantly lower in neoplastic mast cells of patients 
with advanced SM as compared to patients with indolent SM. Thus, SETD2 impaired/loss of 
function can be considered a general phenomenon in SM, with the extent of SETD2 down-
modulation and H3K36 trimethylation deficiency correlating with the aggressiveness of the 
disease. Interestingly, we uncovered that in the great majority of SM patients, SETD2 loss of 
function is accomplished via a novel post-translational mechanism of hyperubiquitination and 
enhanced degradation of the protein, and that inhibition of proteasome-mediated degradation is 
able to rescue SETD2 expression and function. We identified MDM2 as the major ubiquitin E3 
ligase responsible for SETD2 hyperubiquitination, and demonstrated that phosphorylation by 
Aurora kinase A is the main trigger. We also found that SETD2 loss of function disrupts the p53 
checkpoint and correlates with increased DNA damage as a result of reduced recognition of 
double strand breaks by the homologous recombination machinery. We then tested in vitro in cell 
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lines and primary patient cells novel therapeutic approaches aimed to revert SETD2 non genomic 
loss of function: the proteasome inhibitor bortezomib; the MDM2 inhibitor SP-141; the Aurora 
kinase inhibitor danusertib. We also found that the clinical activity of midostaurin (a multi-target 
kinase inhibitor recently approved for the treatment of advanced SM) relies not only in KIT 
tyrosine kinase inhibition, but also in the partial inhibition of Aurora A, and that SETD2 loss of 
function may serve as a biomarker of response to midostaurin. Finally, we investigated the clinical 
significance of SETD2 loss of function in a cohort of 88 patients with various forms of SM assessing 
the prognostic value of SET2 and H3K36 trimethylation levels in the context of other relevant 
clinical and laboratory variables, and found that reduced SETD2 and H3K36 trimethylation levels 













2.1 Systemic mastocytosis 
Mastocytosis results from a clonal proliferation of morphologically and immunophenotypically 
abnormal mast cells. For many years, mastocytosis was believed to be a disease of the skin. A first 
description of the typical (pigmented) skin lesions was provided by Nettleship and Tay in 1869. A 
few years later, the term urticaria pigmentosa was coined, and following Paul Ehrlich’s description 
of MCs in 1879, the presence and accumulation of MCs in urticaria pigmentosa lesions was 
recognized by Unna in 1887. However, in 1949, Ellis described a first case of systemic 
mastocytosis. Over time since this observation, systemic mastocytosis has become a well-
recognized diagnostic entity, although other patients were found to have urticaria pigmentosa 
without systemic involvement1.  
Normal MCs play an important role in the regulation of immunoglobulin E (IgE)–mediated allergic 
responses, inflammation, and the innate and adaptive immune responses to infection1. Abnormal 
activation and accumulation of MCs can lead to mediator symptoms and organ damage. Following 
activation and degranulation, mast cells secrete and generate a host of mediators that contribute 
to allergic inflammation. The disease manifestations exhibited in mastocytosis are a consequence 
of increased mast cells present in tissue and the degree of release of mast cell mediators. The 
clinical features associated with mast cell mediators are pruritus, flushing, urticaria,fatigue, weight 
loss, cachexia, hypotension, swelling,  gastritis, intestinal cramping, osteoporosis, 
bronchoconstriction. Mast cell mediator release causes both local tissue and distal inflammation 
as they are released into the bloodstream. Clinically, the most significant mediator is histamine 
but also prostaglandin D2 and leukotriene C4, interleukin-3 (IL-3), IL-16 and tissue necrosis factor-
α (TNF-α)2. The clinical presentation is heterogeneous, ranging from skin-limited disease 
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(cutaneous mastocytosis [CM]), particularly in children, to varying degrees of extracutaneous 
involvement (systemic mastocytosis [SM]), generally seen in adults1. The World Health 
Organization (WHO) included Mastocytosis from 2008, and recognizes several SM variants3. 
Indolent SM (ISM) is predominantly characterized by symptoms related to mast cell 
degranulation/mediator release and/or allergies or anaphylaxis3,4. In contrast, advanced 
mastocytosis variants (aggressive SM, mast cell leukemia and SM with associated hematologic 
neoplasm) are characterized by organ dysfunction related to mast cell infiltration4,5. Some 
mastocytosis patients present concurrently with, or subsequently develop, an associated clonal 
hematological non mast cell lineage disease, generally a myeloid neoplasm6. Most adult 
mastocytosis patients, regardless of disease subtype, harbor the KITD816V mutation, which has 
pathogenetic and diagnostic relevance3. 
 
2.1.1 Epidemiology of Systemic mastocytosis 
A prevalence of mastocytosis of 1 in 10000 inhabitants has been reported, but underdiagnosis is 
assumed. 
There were no epidemiologic studies defining  the precise incidence, point prevalence, or 
cumulative prevalence of mastocytosis in the general population until the last two decades. In fact 
firm criteria for the diagnosis of mastocytosis have only been defined in 2001 and after this 
diagnosis has become more recognized7,8.  The European Competence Network on Mastocytosis 
(ECNM) attempts to ensure a good quality of diagnosis by defining reference and excellence 
centres for mastocytosis.  When the number of patients in several competence centres were 
analyzed, a steep increase in the number of SM patients was noted from 1998 to 2010, which is 
very likely the result of increased experience and recognition of the disease in this area during 
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these years. At the consensus meeting of mastocytosis experts in Boston 2010, a general 
cumulative prevalence of approximately 1 in 10,000 persons was estimated8,9.  
Mastocytosis can occur in children and adults. Although mastocytosis can occur at any age, the 
onset of mastocytosis is in the first 2 years of life in 50% or more of cases. In adults, most patients 
are diagnosed in middle age between 20 and 50 years of age10. Because of a chronic nature and 
low regression rate of adult-age mastocytosis the cumulative prevalence of adult patients of 
mastocytosis rises with age. Gender distribution is approximately equal11.  
 
2.1.2 Classification of Systemic mastocytosis 
The first attempt to classify the mastocytoses was made in 1979 by the pathologists Lennert and 
Parwaresch of Kiel, Germany12. After various modifications, in 2000 an international group of 
experts agreed on the categorization that was then adopted by the WHO in 20018.  
The updated WHO classification of 2016 divides cutaneous mastocytosis into maculopapular 
cutaneous mastocytosis (MPCM), also known as urticaria pigmentosa, diffuse cutaneous 
mastocytosis (DCM), and localized mastocytoma of skin. Specific criteria of cutaneous 
mastocytosis have been defined and published by the consensus group13-15. Most patients with 
cutaneous mastocytosis are children. In contrast, in most adult patients, systemic mastocytosis is 
detected. The major criterion of systemic mastocytosis is the multifocal accumulation and 
clustering of MCs (at least 15/ cluster) in the bone marrow or another extra-cutaneous 
organ7,8,13,14. Minor systemic mastocytosis criteria confirm the clonal (neoplastic) nature of the 
disease and include an abnormal MC morphology (spindling), expression of CD2 and/or CD25 in 
MCs in extracutaneous organs, expression of an activating mutation in codon 816 of KIT (usually 
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KIT D816V) in extra-cutaneous cells, and a basal serum tryptase level exceeding 20 ng/mL (Table 
1).    
 
 
Table 1. Diagnostic criteria for Systemic mastocytosis (SM) 
 
Systemic mastocytosis is further divided into indolent systemic mastocytosis (ISM), smoldering 
systemic mastocytosis (SSM), systemic mastocytosis with an associated hematologic (non-MC-
lineage) neoplasm (SM-AHN), aggressive systemic mastocytosis (ASM), and MC leukemia (MCL) 
16,17. The provisional variant termed isolated bone marrow mastocytosis (BMM) have been 
described where the disease is essentially restricted to the bone marrow and the tryptase level is 
low or normal18,19. 
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The extent of organ infiltration and subsequent organ damage serve as a basis for the WHO 
classification of SM as indolent SM or advanced SM (AdvSM). Diagnosis of SSM requires two or 
more “B” findings, that include BM biopsy showing >30% mast cell infiltration and/or serum 
tryptase >200 ng/mL; signs of dysplasia or myeloproliferation in non-mast cell lineages with 
normal blood counts; hepatomegaly without impairment of liver function, and/or splenomegaly 
without hypersplenism, and/or lymphadenopathy on palpation or imaging. On the other hand, 
ASM is defined by the presence of at least one “C”-finding, such as: one or more cytopenia(s) in 
absence of non-mast cell hematopoietic malignancy; hepatomegaly with impairment of liver 
function; splenomegaly with hypersplenism; malabsorption with weight loss due to 
gastrointestinal mast cell infiltrates; large osteolytic lesions and/or pathological fractures20. 
A distinct entity that does not belong to the SM is the Monoclonal mast cell activation syndrome 
(MMAS), that is described in patients with anaphylaxis and clonal mast cells expressing the D816V 
mutation in KIT and expressing the a-chain of the interleukin-2 receptor CD25, but without the full 
set of criteria needed to diagnose mastocytosis21. The frequency of MMAS varies among different 




Table 2.  WHO classification of Mast Cell Disease 
 
 
2.1.3 Prognosis of disease and new prognostic score  
The life expectancy of patients affected by SM, when considered as a group, appears to be shorter 
as compared to age-matched and gender-matched controls, with the excess deaths in this group 
occurring within the first 3-5 years after diagnosis (Figure 1)22. The WHO classification is most 
widely used for prognostication and has been validated in multiple studies: although indolent 
mastocytosis is generally not fatal, other forms (e.g. MCL and ASM) usually have a rapidly 
devastating outcome.  
It is commonly believed that most patients with initial ISM had a normal life expectancy. This is 
derived from data published in 2009 from Mayo Clinic, where in a retrospective study of 342 











The prognosis of patients with adult ISM has been studied in a long-term follow-up of 145 
consecutive adult patients observed for a median of 147 months by the Spanish group of REMA23. 
The results show that the disease was stable in most patients. There were signs for biologic 
progression indicating an increased proliferation of mast cells, such as an increase in serum 
tryptase greater than 200 ng/mL, osteoporosis, or organomegalies in 27% of patients. Only five 
patients (3%) showed progression from ISM to a more advanced form of SM, and a cumulative 
probability of disease progression in ISM of 1.7% in 10 years. The REMA group have recently 
updated the case studies and reported 14 of 200 ISM patients that has progressed after a median 
follow-up of 9 years24. They investigated the frequency and prognostic impact of variants in 18 
genes, found to be altered in advSM, and detected genetic variants in 55 of 322 (17%) patients. 
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Mutated ISM cases, particularly those carrying ASXL1, RUNX1, and/or DNMT3A (A/R/D) with a high 
variant allele frequencies (VAFs) ≥30%, exhibited significantly shortened progression-free survival 
(PFS) and overall survival (OS). Multivariate analysis showed that serum b2-microglobulin levels > 
2.5 mg/mL, together with a KIT D816V VAF ≥1% in bone marrow  and pathogenic variants of 
A/R/D, were the best combination of independent predictors for PFS. Based on these variables, 2 
scoring systems were constructed for risk stratification of ISM at diagnosis with significantly 
different 10-year PFS (100%, 91%, 0% for scores of 0, 1, ≥2, respectively) and OS (100% and 50% 
for scores of 0 and 1) rates24. The authors suggest that multilinear KIT, together with mutations in 
genes other than KIT, might provide the genetic background required for disease progression and 
death but the data are still limited about the frequency and potential prognostic impact of 
mutations in genes other than KIT in ISM.  
Several prognostic scoring system have been recently proposed to improve risk stratification in 
advSM25-28. Clinical and genetic informations have been combined. The somatic mutations in 
addition to KIT D816V (eg, in ASXL1, CBL, JAK2, RUNX1, SRSF2, EZH2 or TET2), being present in 
more than 60% of patients with AdvSM have been included in the molecular characterization of 
patients. 
In the study of Jawhar et al. a spleen volume > 450 mL on magnetic resonance imaging and an 
elevated level of serum alkaline phosphatase (AP) were both associated with inferior survival in a 
multivariate analysis25. In this series of 108 patients with indolent (n = 41) and advanced systemic 
mastocytosis (advSM, n = 67) they distinguished a 3-year OS of  100, 77, and 39%, respectively 
(P<0.0001), for patients with 0 (low risk, n = 37), 1 (intermediate risk, n = 32) or 2 (high risk, n = 39) 
parameters. For advSM patients with fully available clinical and molecular data (n = 60), univariate 
analysis identified splenomegaly ≥ 1200 ml, elevated AP and mutations in the SRSF2/ASXL1/RUNX1 
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(S/A/R) gene panel as significant prognostic markers. In multivariate analysis, mutations in S/A/R 
and elevated AP remained predictive adverse prognostic markers for OS. The 3-year OS was 76 
and 38%, respectively (P = 0.0003), for patients with 0–1 (intermediate risk, n = 28) or 2 (high risk, 
n = 32) parameters25.  
The MARS score combined clinical and molecular parameters in a study that included 383 patients 
with AdvSM: in multivariable analysis, the risk factors identified as being associated with OS were 
age greater than 60 years, anemia (hemoglobin , 10 g/dL), thrombocytopenia (platelets , 100 >  
109/L), presence of one high molecular risk gene mutation ( SRSF2, ASXL1, and/or RUNX1), and 
presence of two or more high molecular risk gene mutations. By assigning hazard ratio–weighted 
points to these variables, the following three risk categories were defined: low risk (median OS, 
not reached), intermediate risk (median OS, 3.9 years; 95% CI, 2.1 to 5.7 years), and high risk 
(median OS, 1.9 years; 95% CI, 1.3 to 2.6 years; P  <001). The mutation-adjusted risk score (MARS) 
was independent of the WHO classification and was confirmed in the independent validation set. 
During a median follow-up time of 2.2 years (range, 0 to 23 years), 63 (16%) of 383 patients 
experienced a leukemic transformation to secondary mast cell leukemia (32%) or secondary acute 
myeloid leukemia (68%)26-27.  
The Mayo prognostic score was elaborated on the total of the 580 patients seen at the Mayo Clinic 
between 1968 and 2015 combining the clinical and genetic characteristics (diagnosis of SM was 
per WHO criteria, karyotype and next-generation sequencing data were available in a subset of 
patients) of the patients with SM.  Multivariable analysis of clinical variables identified age >60 
years, advanced SM, thrombocytopenia <150 x 109/L, anemia below sex-adjusted normal, and 
increased alkaline phosphatase (AP) as independent risk factors for survival. In addition, ASXL1, 
RUNX1, and NRAS mutations were independently associated with inferior survival28.  
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To date, the independent prognostic value of most variables and proposed risk scores has been 
derived from relatively small sets of patients, and they have not been confirmed or validated.  
 
2.2 Advanced Systemic Mastocytosis 
AdvSM includes patients with SM and an associated hematologic neoplasm (SM-AHN), aggressive 
SM (ASM), and mast cell leukemia (MCL)7,29-31. In contrast to indolent SM, AdvSM has a poor 
prognosis32. The overall survival (OS) of patients with AdvSM ranges from a few months to several 
years, with a median OS of approximately 4 years33. 
 
2.2.1 Aggressive Systemic Mastocytosis 
ASM was the third most common subgroup (n = 41; 12%) in series of Lim et al22. In ASM , organ 
systems typically involved with C-findings are the BM, with severe anemia (Hb <10 g/dL; 24%) or 
thrombocytopenia(platelets <100×109/L; 27%), liver (hepatomegaly, ascites, increased liver 
enzymes), spleen (50%), bones (osteolysis, pathologic fractures), and the gastrointestinal tract 
(malabsorption, weight loss). Patients frequently displayed constitutional symptoms (60%), 
lymphadenopathy (30%) and markedly elevated serum tryptase levels (>200 ng/mL; 40%)34. An 
important aspect of ASM is that the disease can presents as slowly progressing ASM (similar to 
SSM but with C-findings) or rapidly progressing ASM. Overall median survival in ASM was 41 
months31.  
 
2.2.2 Systemic Mastocytosis with an Associated Hematologica Neoplasia (SM-AHN) 
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SM-AHN (70% to 80% of all patients with AdvSM) is the most heterogeneous and clinically 
challenging subtype of AdvSM. The AHN usually resembles a myeloid neoplasm (eg, chronic 
myelomonocytic leukemia, myelodysplastic/myeloproliferative neoplasm unclassifiable, chronic 
eosinophilic leukemia, or myelodysplastic syndrome). Histopathologic evaluation of SM-AHN 
merits special consideration because of its associated diagnostic complexity and potential impact. 
In the Mayo series, the median OS of SM-AHN patients was 2 years22. Although the prognosis of 
SM-AHN frequently relates to the AHN component, marked heterogeneity in outcomes exists 
between AHN subtypes (ie, average survivals of 31, 15, and 13 months for SM-MPN, SM-CMML, 
and SM-MDS, respectively)22-35. 
In the vast majority of patients, the phenotypically most important somatic mutation (ie, KIT 
D816V) is detectable in the clonal mast cell compartment and in cells derived from the AHN36,37. 
 
2.2.3 Mast cell leukemia   
Mast cell leukemia (MCL) is a rare form of systemic mastocytosis characterized by leukemic 
expansion of mostly immature mast cells, organ damage, drug-resistance, and a poor prognosis. In 
a recent retrospective analysis a median OS survival of 9.4 moths is reported, with 42.9% of 
patients alive at 12 months, 23.2 patients alive at 36 months and 16.% alive at 5 years. These data 
are very different from what was thought before, maybe influenced by the therapies38. In the 
series of Mayo Clinic of 2009 the median OS for MCL was < 4 months22.  
In patients with MCL, KIT mutations are detected less frequently then in the other forms. Here 
neoplastic MCs display KIT D816V in only 50-70% of the cases. In the remaining MCL cases, other 
KIT mutations or no KIT mutations are found. in most patients with MCL, most MCs in BM smears 
are immature, tryptase level is quite low, and more frequently the skin is undamaged. The cell 
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surface phenotype of MCs in MCL is quite similar when compared to the cell surface membrane 
phenotype of MCs in other variants of SM. The new entity of Chronic Mast cell leukemia has been 
proposed by Valent,  characterized by relatively long survival and specific morphological features 
(a majority of all MCs have a more mature morphology)39.  
 
2.2.4 Therapy of AdvSM  
Therapeutic options for patients with newly diagnosed ASM, SM-AHN, and MCL are represented 
today by Midostaurin, Cladribine, Interferon and Allogeneic hematopoietic stem cell 
transplantation40. Clinical trials are ongoing with Avapritinib, a KIT and PDGFRα inhibitor 
specifically designed to inhibit KITD816V. Early results from a Phase 1 trial suggest that avapritinib 
has potent antineoplastic activity in AdvSM, extending to patients who failed midostaurin, and 
clinical trials are ongoing in several centers. Midostaurin has been approved for all 3 AdvSM 
subtypes, irrespective of KIT mutation status in 2017 by Food and Drug Administration and in 2018 
by European Medicines Agency. For patients with SM-AHN, a determination must first be made 
regarding whether treatment is needed and which component requires more immediate therapy 
(the SM component or the AHN). Cladribine and [pegylated]–interferon-a with or without 
prednisone have been used on an off-label basis for all 3 advSM variants; Cladribine (2-
chlorodeoxyadenosine [2-CdA]) is a synthetic purine analog cytoreductive treatment, whose 
efficacy is mostly reported in advanced SM. Standard administration consists of 5 days of 0.14 
mg/kg infusion or subcutaneous administration, repeated until 9 courses. The reported overall 
response rate was 72%, with clinical improvement in mediator release, mast cell infiltration ( 
including urticaria pigmentosa) and serum tryptase levels decrease. It is preferred in patients 
requiring rapid debulking of disease, whereas interferons are preferred in slow progressors34. 
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Imatinib is approved for the rare ASM patients who are KIT D816V mutation negative or whose KIT 
mutation status is unknown. For patients with eosinophilia, rule out FIP1L1-PDGFRA positivity, 
because such neoplasms are very sensitive to imatinib. Allogeneic hematopoietic stem cell 
transplantation (HSCT) may be considered as initial therapy for ASM or SM-AHN. Bone marrow 
transplantation is recommended as frontline treatment of MCL, but it may be considered for 
individuals achieving substantial clinical benefit with midostaurin, cladribine, or a clinical trial 
drug31,42. Multiagent chemotherapy as initial treatment of MCL is not recommended today. 
Corticosteroids may be used on a short-term basis for rapidly progressive SM-related organ 
damage. Symptom-directed treatment should be considered in all SM patients, also during 
cytoreductive therapy. Anti- mediator therapies for SM are directed at MC 
degranulationsymptoms (eg, pruritus, urticaria, angioedema, flushing, nausea, vomit-ing, 
abdominal pain, diarrhea, episodic anaphylactoid attacks), symptomatic skin disease (eg, urticaria 
pigmentosa) and/or osteope-nia/osteoporosis/pathologic fractures31. 
The most attractive therapy is Midostaurin, for its peculiar mechanism of action, that potently 
target activation loop mutants of KIT receptor, cementing the view that KITD816V represents the 
driver mutation for SM. Midostaurin was originally termed PKC412, and is a semi-synthetic 
derivative of the alkaloid staurosporine, a well-known inhibitor of PKC (Figure 2)41. Although 
initially considered a rather specific pharmacologic inhibitor of PKC, midostaurin interacts with a 
broad spectrum of clinically relevant kinase-targets, including KIT and other KIT mutants, FLT3, 
platelet-derived growth factor receptor alpha (PDGFRA), PDGFRB, vascular endothelial growth 
factor receptor KDR, and the Aurora kinasi A and B (Table 3)41. 
In the global Phase 2 CPKC412D2201 trial, 116 patients with advanced SM were enrolled; the 
primary efficacy population comprised of 89 patients (16 with ASM, 57 with SM-AHN, and 16 with 
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MCL); patients were treated with PKC412 at 100 mgBID83. The ORR per conventional criteria was 
60% with 45% having a major response and 15% having a partial response. The response rate was 
75% in ASM patients, 58% in SM-AHN patients and 50% in MCL patients. After a median follow up 
of 26 months (range 12-54), the median duration of response was not reached in ASM or MCL 
patients and was 12.7 months in SM-AHN patients. Responses occurred regardless of KITD816V 
status. The median OS for ASM, SM-AHN and MCL subgroups was not reached, 20.7 months and 





Figure 2. Chemical structure and anti-neoplastic effects of midostaurin. (A) Chemical structure of 
staurosporin and its derivative midostaurin. (B) anti-neoplastic effects of midostaurin on the 
human mast cell lines ROSA
KIT WT
 (left panel) and ROSA
KIT D816V
 (right panel) (C) anti-neoplastic 






  Major target cell populations and disorders  
KIT wt  Mast cells, AML blasts, GIST cells  
KIT D816V  Mast cells in SM, AML blasts, GIST cells  
KIT V560G  Mast cells in SM, GIST cells  
KIT K509I  Mast cells in CM  
FES  Mast cells in KIT D816V+ SM  
  (KIT D816V-downstream-signaling)  
FLT3 wt  Myeloid (progenitor) cells  
FLT3 ITD  AML blasts  
FLT3 D835H  AML blasts  
FLT3 D835Y  AML blasts  
FLT3 N841I  AML blasts  
PDGFRA wt  Fibroblasts, mesenchymal stem cells  
FIP1L1-PDGFRA 
(F/P)  Eosinophils, CEL, MPN-eo  
F/P mutant forms  Eosinophils, CEL, MPN-eo  
PDGFRB wt  Fibroblasts, mesenchymal stem cells  
PDGFRB mutant 
forms  Eosinophils, CEL, MPN-eo  
JAK2  Myeloid cells, MPN cells  




  Major target cell populations and disorders  
AAK1  Notch adaptor in neoplastic cells  
SYK  IgE-R+ cells, IgE-R-downstream signaling  
AURKA  Mitosis regulator in various neoplastic cells  
AURKB  Mitosis regulator in various neoplastic cells  
MARK3  Oncogenic molecule in hepatocellular cancer  
PKN1  Wnt/β-catenin repressor in cancer cells  
FGFR3  B cells, multiple myeloma cells  
FGFR3 TDII (K650E)  B cell lymphoma cells, multiple myeloma cells  
TEL-FGFR3  T cell lymphoma cells, MPN, AML blasts  
 
Table 3. Molecular targets of Midostaurin 
 
2.3 Genomic landscape of mastocytosis  
The mechanisms involved in the development of mastocytosis are mainly unknown. The presence 
of gain-of-function mutations involving the tyrosine kinase domain of c-kit is used as diagnostic 
criteria, and activation of kinase pathways (i.e. D816V mutation of KIT) have previously been 
shown to be relevant for development of disease. In adult patients, the frequency of the D816V 
KIT mutation varies from 75% to virtually all cases. Mastocytosis may occur also in absence of 
mutations in the oncogene KIT, indicating that the molecular reasons behind this disease are 
variable, they do not depend on a single mutation or oncoprotein, and they could have both 
genetic and epigenetic basis. Further molecular knowledge are arising today, but given the 
heterogeneous clinical behavior it seems quite likely that more than one pathway are altered in 
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the disease and the identification of others genetic alterations or mechanisms concurring to 
disease presentation are warranted. Studies of gene expression profile have identified 
differentially expressed genes in patients affected by indolent systemic mastocytosis compared 
with healthy controls. They involve the ubiquitin-mediated proteolysis, MAPK signaling pathway, 
Jak-STAT signaling, and p53 signaling pathway, with influence on transcription, cell cycle, protein 
transport, and signal transduction44. The studies by Garcia-Montero showing that the KIT mutation 
is present not only in mast cells but also in myeloid and lymphoid cell lineages seems to be 
relevant to establish the prognosis of patients with indolent mastocytosis45, with important 
implications on therapeutic approach to these patients.  
 
2.3.1 c-kit 
Molecular pathogenesis of mastocytosis involves acquisition of c-KIT mutations, particularly 
D816V, which is present in a majority of all patients with SM, irrespective of WHO SM subtype, 
including ISM, ASM, or MCL24,46,47. Type III RTKs consist of a glycosylated extra-cellular ligand-
binding domain (ectodomain) connected to a cytoplasmic region by means of a single 
transmembrane helix. The cytoplasmic region of KIT is composed of an auto-inhibitory juxta-
membrane region (JMR) and a protein tyrosine kinase (PTK) that is subdivided into proximal and 
distal lobes separated by an insert sequence of variable length (70–100 amino acids). In human 
KIT, the 77-amino acid kinase insert domain (KID) possesses phosphorylation sites and provides an 
interface for the recognition of pivotal signal transduction proteins. KIT is notably expressed by 
MC, hematopoietic progenitor cells, germ cells, melanocytes, and interstitial cells of Cajal in the 
gastrointestinal tract 48. KIT expression is down regulated during differentiation of hematopoietic 
progenitors into mature cells of all lineages, but MCs retain high levels of cell surface KIT 
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expression. Binding of SCF to KIT leads to receptor dimerization, intermolecular auto-
phosphorylation of specific tyrosine residues and PTK activation. The activation process involves a 
large rearrangement of the activation loop (A-loop, ,20–25 residues) of PTK. Conformational 
switch of A-loop from an inactive packed position to an active extended form releases access for 
Mg2+ -ATP and protein substrate(s) to the kinase catalytic site49. A variety of mutations of KIT 
were found in different types of human cancer, in gastrointestinal stromal tumors (GISTs), acute 
myeloid leukemia (AML), mast cell leukemia (MCL) and human germ cell tumors, among others 
and they induce the activation of tyrosine kinases. Longley et al. early proposed a classification of 
KIT gain-of-function mutations according to their structural and functional locations50. The JMR 
mutations, frequently found in GISTs, are considered regulatory as they disrupt the auto-inhibitory 
mechanism which negatively regulates the activity of the protein. The PTK mutations are 
considered catalytic as they directly affect the configuration of the enzymatic site probably by 
stabilizing the A-loop extended conformation. To this category belongs the mutation D816V found 
in mastocytosis, that also confer resistance to Imatinib treatment51. Other somatic KIT mutations 
were  identified in adult SM, even if they are less common (<5%): D815K, D816Y, insVI815-816, 
D816F, D816H, and D820G. All these mutations mapped in exon 17 of KIT, that corresponds to the 
activation loop region; other point mutations, as V560G, are mapped in exon 8 or exon 9 of KIT, in 
the juxtamembrane region of the receptor. Mutations described primarily in pediatric cases with 
cutaneous mastocytosis (CM) are located in exon 7, 9 and exon 11 : C443Y, S451C, S476I, D572A 
and frequently the molecular alterations are represented in these cases by insertions, deletion and 





Figure 3. Overview of KIT mutations described in patients with mastocytosis. ABD, ATP-binding 
domain; Del, deletion; ECD, extracellular domain; Ins, insertion; ITD, internal tandem duplication; 
JMD, juxtamembrane domain; KI, kinase insert; PTD, phosphotransferase domain; TMD, 
transmembrane domain. The asterisk denotes KIT mutations that have also been described in other 
neoplasms such as GIST, acute myeloid leukemia (AML), lymphomas, or seminomas.  
 
Several observations suggest that KIT D816V alone is not a fully transforming oncoprotein. While 
activating KIT mutations are frequently associated with human mastocytosis, they do not occur 
universally, and the different natural history of childhood- and adult-mastocytosis, with the former 
often exhibiting skin-limited disease that spontaneously regresses with age; in contrast, the latter 
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characterized by persistent multi-organ involvement, often with second non-MC hematologic 
neoplasm, should be related to different biological pattern, but experimental data with regard to 
this issue have not been conclusive52. 
 
2.3.2 Myeloid mutations 
Schwaab et al. for the first time reported on the identification of a variety of additional mutations 
in 89% of patients with advanced KIT D816V positive SM. The most frequently affected genes were 
TET2, SRSF2, ASXL1, RUNX1 and CBL. (Blood, 2013)53. Subsequent studies addressed the issue of 
the presence of additional mutations, and their role as prognostic factors.  Hence, recent studies 
based on relatively limited gene panels have shown that advanced forms of SM, including 177 of 
284 SM-AHN cases, 28 of 284 ASM cases, and 8 of 284 MCL cases, often carry mutations in genes 
previously reported to be altered in other myeloid neoplasms, in addition to the KIT mutation36,53-
55. However, relatively limited information exists about the frequency of mutations in those genes 
in diagnostic subtypes of SM other than SM-AHN (eg, ISM and smoldering SM in addition to ASM 
and MCL). Also, these mutations have been found in the other hematological neoplasm 
component of the disease but not always in the MC compartment35. In addition, it remains 
unknown whether the occurrence of such mutations in an early hematopoietic precursor would 
also confer a worse prognosis to SM patients, as demonstrated by Jawhar et al for SM-AHN cases 
and previously reported for KIT D816V55. 
 
2.4 Next generation sequencing technologies 
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Driven by incredibly rapid technological advances, medicine, genetics and molecular biology have 
indeed witnessed in recent years a deluge of new experimental methods for interrogating 
different properties of a cell on a genome-wide scale. Each technology offers a unique, although 
complementary, view of genome organization and cellular functions and therefore allows the 
identification of specific molecular alterations of tumor cells, such as aberrant gene expression 
profile signatures, driver mutations, structural genomic rearrangements, novel gene fusions and 
methylation patterns. Next Generation Sequencing (NGS) technologies, overcoming the limited 
scalability of traditional Sanger sequencing, are recently revolutionizing genomics and 
transcriptomics by providing a cost-efficient and single base resolution tool for a unified deep 
analysis of tumor complexity56. Systemic Mastocytosis, an uncommon disease with heterogeneous 
clinical presentation and different prognosis, with the unique known genetic lesion involved in the 
pathogenesis represented by specific KIT mutation, may constitute an exciting field of application 
for these techniques.  
 
2.5 The index case 
A 65-year-old Caucasian woman presented to emergency department because of flushing and 
hypotensive shock. She did not show serum biochemistry alterations, except for serum total 
tryptase levels of 2255 ng/mL (normal value: <13.0), haemoglobin 10.2 g/dL, total white blood cell 
count (WBC) 15980 × 109/L, and platelets 319000 × 109/L. She was referred to the hematology unit 
some days later and the high serum tryptase level was confirmed. She had 50–60% infiltration of 
atypical MCs on bone marrow smears and 70–80% on biopsy. Neoplastic MCs showed bright 
expression of CD117, positivity of CD2, and negativity of CD25 antigen; the morphological 
examination of peripheral blood smear showed <1% of MCs, so she was diagnosed as aleukemic 
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variant of MCL. Direct sequencing of the entire KIT gene on bone marrow and peripheral blood 
tested negative for the KIT D816V mutation and for any other mutation (primers are reported). 
Due to the asymptomatic presentation, she was given antihistamine alone for five months. Then, 
the appearance of anemia (9.7 g/dL), with serum tryptase level steadily around 2000 ng/mL, 
prompted starting therapy with imatinib 400 mg/die, that was indicated on the basis of the 
absence of KIT mutations. The patient maintained a stable disease for twelve months when on 
imatinib, then imatinib had to be stopped due to increasing anemia and no substantial response. 
The subsequent therapy with dasatinib did not have any effect and the patient died due to 
haemorrhagic stroke in disseminated intravascular coagulation, three weeks after dasatinib 
initiation and twenty-four months after initial symptoms.  
We undertook an integrated molecular genetic study of this KIT gene mutation-negative MCL case. 
After having obtained written informed consent, we extracted genomic DNA and total RNA from 
purified mast cells (MCs) isolated from bone marrow at diagnosis and at progression, as well as 
DNA from saliva, and performed whole exome sequencing (WES) and RNA-seq on an HiSeq1000 
(Illumina, San Diego CA). Among the mutated genes detected in MCs but not in saliva by WES, 
SETD2 stood out among others because two loss-of-function mutations: a nonsense mutation in 
exon 15 (NM_014159:c.G6753T:p.Glu2234Ter) and a frameshift insertion of a C in exon 20 
(NM_014159:c.7595_7596insC: p.Gly2515ArgfsTer5). Both were validated by Sanger sequencing 
(Figure 4a). The first mutation was predicted to result in a truncated protein lacking 330 amino 
acids at the C-terminal whereas the second mutation was predicted to result in a truncated 
protein lacking 46 amino acids at the C-terminal (Figure 4b). The result was the inactivation of 
both alleles of the gene. Western Blotting (WB) confirmed the expression of the truncated SETD2 
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isoform (tSETD2) resulting from the nonsense mutation. tSETD2 was predicted to lose the highly 




Figure 4. SETD2 loss of function mutations in the index MCL case (MCL1). (a) Sanger sequencing 
chromatograms with the frameshift (top) and nonsense (bottom) mutations identified by whole-
exome sequencing. (b) Localization of the mutations with respect to the key functional domains of 
the SETD2 protein. The SRI domain is necessary for histone H3 lysine 36 trimethylation (H3K36Me3) 
and mediates SETD2 interaction with the phosphorylated C-terminal domain of the RNA 
polymerase II large subunit (RNA pol II) and with the heterogeneous nuclear ribonucleoprotein-L 
(HnRNP), thus coupling H3K36Me3 with transcription elongation and splicing. (c) from top to 
bottom: western blotting (WB) showing the truncated SETD2 (tSETD2) protein as compared to full-
length SETD2 detectable in a pool of proteins from mononuclear cells of healthy donors; co-
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immunoprecipitation experiments performed by using: an anti-RNA pol II, an anti-hnRNP and an 
antihistone H3, respectively, to isolate the proteins of interest and then an anti-SETD2 as primary 
antibody to label the PVDF membrane on which the immunoprecipitates were transferred; WB for 
H3K36Me3. Histone H3 and actin were used as loading controls.  
 
2.6 SETD2 gene 
The human SETD2 gene is located at the cytogenetic band p21.31 of chromosome 3, a region 
frequently targeted by copy number loss in various tumors . SETD2 encompasses a genomic region 
of 147Kb, and the 21 exons encode an 8,452nt transcript. The SETD2 protein consists of 2,564 
amino acids and has a molecular weight of 287.5 KD. Three conserved functional domains have 
been identified in the SETD2 protein: the triplicate AWS-SET-Post SET domains, a WW domain and 
a Set2 Rpb1 interacting (SRI) domain (Figure 5). The SETD2 gene encodes a histone methyl-
transferase responsible for trimethylation of Lysine 36 of Histone H3 (H3K36Me3)57, a key hystone 
mark associated not only with active chromatin but also with transcriptional elongation, 
alternative splicing, DNA replication and repair58. SETD2 has indeed a key role in maintaining the 
integrity of the genetic information at the DNA and transcript level, and specifically in: i) 
preventing aberrant transcription through binding to the C-terminal domain of the RNA 
polymerase II (PolII)59; ii) regulating splicing through association with the large subunit of the 
heterogeneous nuclear ribonucleoprotein complex (hnRNP-L)60; iii) participating both in 
Homologous Recombination (HR) repair after a double strand break (DSB) has occurred61 as well 
as in Mismatch Repair (MMR) during DNA replication62 vi) activating p53-dependent cell cycle 
checkpoint (Figure 6)62,63.  
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In recent years, SETD2 has attracted a lot of interest as a gene whose inactivation is involved in 
tumor initiation and progression.  
 
 
Figure 5.  Structure of SETD2protein 
 
Figure 6.  Schematic representation of SETD2-mediated trimethylation of H3K36 and an overview 
of the H3K36me3 readers that define its role in various biological processes. 
 
2.6.1 Mutations of SETD2 gene 
 33 
The first report on SETD2 mutations in cancer dates from 2010 when Dalgliesh et al identified 
inactivation mutations in ccRCC64,65. This bi-allelic inactivation of SETD2 was the first clue that the 
gene might be a tumor suppressor gene. Two large cohort studies revealed an overall frequency of 
SETD2 mutations of approximately 11% in clear-cell Renal cell carcinoma (ccRCC). Still, whole-
exome sequencing studies did reveal somatic SETD2 mutations in various types of cancer including 
lung, breast, skin and brain cancers, and this can be seen as an indication that SETD2 inactivation 
plays a role in the development of other tumors, albeit with low frequencies in most of them. 
Moreover, the majority of somatic SETD2 mutations were missense mutations for which the 
functional consequences are often unclear. In renal cell carcinomas, SETD2 loss of function mainly 
results from large monoallelic deletions or CN-LOH at chromosome 3p, followed by mutation of 
the remaining allele.33 In acute leukemias, it rather derives from biallelic missense or truncating 
mutations. This is illustrated by the study of Zhu et al 66 of 241 cases of leukemia (134 acute 
myeloid leukemia and 107 acute lymphcytic leukemia) in which only 8 of the 19 somatic SETD2 
mutations identified in 15 patients were truncating. Bi-allelic mutations were detected in only 4 
patients. It cannot be excluded that in ALL, and possibly in other tumors as well, SETD2 
haploinsufficiency does lead to a disease phenotype. SETD2 mutations appeared to be most 
frequent in leukemias that carried a MLL gene rearrangement66,67. Loss of function of the SETD2 
tumor suppressor gene, which encodes the only histone methyltransferase that can catalyze 
H3K36Me3, and global loss of H3K36Me3 have been observed to be associated with worse 
prognosis or advanced cancer stage. In gliomas, SETD2 mutations were predominantly seen in 
high-grade (16 out of 178 cases) but not in low-grade cases (0 out of 45 cases)68. Further evidence 
supporting a role of SETD2 inactivation in progression of tumors comes from a recent study 
performed by Ho et al 69. Using immuno-histochemical approaches, Ho et al observed a decrease 
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in H3K36me3 levels in metastatic ccRCC as compared to primary ccRCC69. Either acquired SETD2 
mutations or alternate mechanisms may be the cause of this, suggesting that a decreased level of 
H3K36me3 is correlated with progression. Using whole exome sequencing and H3K36me3-staining 
of tissue sections, they identified different SETD2 mutations in different regions of the same 
primary tumor in three cases. This suggested that loss of SETD2 can be a late event that provides a 
selective advantage to tumor cells70. 
 
2.6.2. Methylation and cancer 
Cancer is characterized by uncontrolled cell growth and acquisition of metastatic properties. In 
most cases, activation of oncogenes and/or deactivation of tumor suppressor genes lead to 
uncontrolled cell cycle progression and inactivation of apoptotic mechanisms. There are different 
mechanisms by which these genetic and cellular changes occur. The canonical mechanisms are 
mutation, chromosomal translocation or deletion, and dysregulated expression or activity of 
signaling pathways. The role of epigenetics in carcinogenesis is less well defined. Recent studies 
suggest that epigenetic alteration may be another hallmark of cancer due to its role in the 
generation of cancer progenitor cells and subsequent initiation of carcinogenesis. Epigenetic 
changes can induce pro-cancer characteristics in even mutation-free cells producing alterations in 
gene expression, independent of changes in DNA sequence. Many epigenetic modifications, such 
as DNA methylation and hydroxymethylation, histone acetylation and methylation, and changes in 
small noncoding RNAs, have profound effects on gene expression. DNA methylation at CpG islands 
has been shown to silence gene expression by interfering with transcriptional machinery. Many 
other epigenetic changes, such as hypomethylation of oncogenes, hypermethylation of tumor 
suppressor genes, depletion of hydroxymethylation, changes of histone acetylation and 
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methylation patterns, and miRNA expression level variations, are known to be associated with 
many cancers. Epigenetic silencing of tumour suppressor genes promotes tumour progression via 
inhibition of apoptosis in cancer cells. Apoptosis is a highly regulated process of cell death in the 
development and maintenance of a normal cell population in mature organisms. Deregulation of 
apoptosis pathways is thus a key feature of carcinogenesis, because the inhibition of natural cell 
death mechanisms plays an important role in tumour progression by permitting abnormal cell 
growth. However, the dynamic nature of epigenetic modification leaves the door open to the 
reversal of cancer-related epigenetic changes by drugs that permit re-expression of pro-apoptotic 
and pro-autophagy tumour suppressors or cell-cycle regulators71. 
 
3. AIM OF THE STUDY 
The overall aim of this project is to assess the prevalence, the underlying mechanisms and the 
effects of SETD2 reduced/loss of function in SM; provide some new elements that can help to 
understand the heterogeneity of the disease from Indolent to the more aggressive forms, with the 
aim of identifying new possible therapeutic targets. 
 
3.1 AIM 1: Study of SETD2 gene inactivation and function in SM 
We identify a new nonsense mutation in the SETD2 gene in a case of MCL negative for any KIT 
gene mutation,  and a consequent reduction in its gene expression.  
We hypothesized that the dowmodulation of SETD2 protein, and corresponding reduction of 
H3K36Me3, could also be observed in a more extensive cohort of cases of advanced SM, and 
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examined more cases of AdvSM and ISM to test this hypothesis. Also, we examined the gene 
alterations, changes in expression, function, interaction with other proteins and cellular 
consequences with functional validation studies conducted on patients’ cell and cell lines models 
to test how this gene down modulation may afford an alternative mechanism of aggressiveness in 
SM. 
 
3.2 AIM2: Clinical implication of SETD2 inactivation in SM  
With our previous results we had demonstrated that MCL and ASM had significantly lower levels 
of SETD2 protein and H3K36Me3 as compared to ISM, with some exceptions. We therefore 
planned to extend the SETD2 evaluation to a greater number of cases of ISM and we collected all 
the clinical data useful to the prognostication of the cases. Once we established the strong 
association of inactivation of SETD2 with the aggressiveness of the disease, we wanted to verify 
which is the clinical impact of the SETD2 gene expression level OS.  After identifying a SETD2 value 
that distinguishes indolent forms from other forms, we analyzed all the clinical features to 
correlate the impact of downmodulation of SETD2/H3K36Me3 on clinical presentation of disease. 
 
4. MATERIALS AND METHODS 
4.1 AIM 1 : Study of SETD2 gene inactivation and function in SM 
4.1.1 Patients samples and cell lines 
 37 
A total of 57 SM patients were included in the validation cohort based on sample availability (23 
patients with ISM (three with SM-AHN), three with SSM, 20 with ASM (three with ASM-AHN) and 
11 with MCL (two with MCL-AHN)) were diagnosed and classified according to WHO criteria3,7,30.  
Mononuclear cells isolated from BM and PB samples were used to extract DNA, RNA and proteins. 
The mononuclear cell fraction (MNC) from bone marrow and peripheral blood samples of patients  
were obtained by means of Ficoll-Hypaque gradient and subsequential centrifugation. Equal 
amounts of RNA and proteins from peripheral blood samples of 8 HDs were pooled to avoid 
individual differences in transcript and protein expression. 
To identify molecular mechanisms involved in SETD2 loss of function we uses two different cell 
lines as in vitro models. HMC-1 cells were cultured in flasks with Iscove's basal medium plus stable 
glutamine, supplemented with 10% v/v FBS, 100 µM penicillin, 100 µg/ml streptomycin and 
incubated at 37 °C in a 5% CO2 atmosphere. Every three days, the cells were pelleted at 700 rpm 
for 5 min and the culture medium was changed. The cells were resuspended in a concentration of 
2×106 cells/ml. HMC-1 cells derived from a mast cell leukemia patient and display two subclones: 
HMC 1.1 harboring V560G mutation and HMC 1.2 harboring both V560G and D816V mutations. 
ROSA cells are a stable stem cell factor (SCF) -dependent human MC line, ROSA(KIT WT), 
expressing a fully functional immunoglobulin E (IgE) receptor. Transfection with KIT D816V 
converted ROSA(KIT WT) cells into an SCF-independent clone 72-75. 
 
4.1.2 Whole exome Sequencing 
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For the DNA sample obtained from CD117+ cells, 155 million reads were generated (coverage, 
114x) with 99.84% mapped reads. For the DNA sample obtained from saliva, 197 million reads 
were generated (coverage, 147x) with 99.77% mapped reads. 
Data analysis was performed following Genome Analysis ToolKit (GATK) best practice as described 
below. Briefly, raw data were inspected to detect low quality reads. Adapters were trimmed out 
when needed and resulting files were aligned to reference genome (hg19) with the Burrows-
Wheeler Aligner (BWA). Picard tool was employed to mark duplicates and indels recalibration step 
was carried out in order to clean up artifacts produced in the initial mapping step. Base quality 
score recalibration (BQSR) was performed to get more accurate base qualities. Recalibrated BAM 
files were subjected to variant discovery by employing MUTECT and VARSCAN analytical tools for 
paired samples76. Variants obtained were filtered against genes known as sequencing artifacts and 
for hyper mutated and polymorphic genes76. A list of high confidence SNVs and indels was 
obtained and annotated for amino acid substitution and SIFT function predictive score76.   
 
4.1.3  Single Nucleotide Polymorphism (SNP)-Array analysis 
Cytoscan HD arrays were processed by NEXUS analysis software to obtain segmented copy 
number variant (CNV) regions across the genome. CNVs smaller than 1kb were filtered out. CNVs 
were filtered against those annotated in the Database of Genomic Variants (DGV) and matching 
ones removed76. 
 
4.1.4 Loss-of-heterozygosity (LOH) analysis at 3p21.3 
 39 
Characterization of the Copy Neutral (CN)-LOH region found by SNP-arrays in 10/13 SM patients of 
the validation cohort revealed that the minimal common region (MCR) of LOH included SETD2 and 
nine additional genes (CCDC12, NBEAL2, NRADDP, KIF9-AS1, KIF9, KLH18, PTPN23, SCAP, ELP6). In 
order to screen for LOH specifically at 3p21.3 in the remaining patients of the validation cohort, 
nine SNPs with Minor Allele Frequency (MAF)>40% were selected in the MCR (rs11720139, 
rs2305634, rs2305635, rs1079276, rs2278963, rs6780013, rs1531875, rs4082155, rs6767907) and 
genotyped. Thirty nanograms of DNA was amplified by polymerase chain reaction (PCR), then the 
sequencing of PCR products was performed on an ABI PRISM 3730XL (Life Technologies). 
 
4.1.5 Sanger sequencing  
SETD2 mutations identified by WES in the index case were validated by Sanger sequencing at the 
genomic level76. 
In the HMC-1.1 and HMC-1.2 cell lines and in the 11 MCL cases of the validation cohort, the entire 
coding sequence of the SETD2 gene (21 exons) was screened for mutations by Sanger sequencing 
on an ABI PRISM 3730XL (Life Technologies) using 30ng DNA and the primers reported in Duns et 
al(37 amplicons)77. In the remaining 46 samples of the validation cohort, SETD2 mutation 
screening was performed by a high throughput approach based on library preparation with the 
Access Array technology (Fluidigm) and sequencing on a MiSeq Instrument (Illumina). The SETD2 
gene was targeted by 52 amplicons. Briefly, 80ng of DNA was used as input material for the Access 
Array, while exon 1 was amplified separately by PCR using a GC-rich enzyme (Roche Applied 
Science). SETD2 was sequenced with a mean coverage of 1,898 for all amplicons and patients, the 
detection limit was set to 3%. The Sequence Pilot software version 4.2.2 Build 502 (JSI Medical 
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Systems) was used for alignment and variant calling. Gene mutations were annotated compared to 
the reference sequence based on the SETD2 Ensembl Transcript ID ENST00000409792 (Ensembl 
release 74: Dec 2013). Analysis parameters were set according to manufacturer’s default 
recommendation. Validity of called variants was checked against the publicly accessible COSMIC 
v73 database (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic), ClinVar (v2015-08-06) 
(http://www.ncbi.nlm.nih.gov/clinvar/), and dbSNP database (http://www.ncbi.nlm.nih.gov/snp; 
Build 137). Functional interpretation was performed using SIFT 1.03 (http://sift.jcvi.org), PolyPhen 
2.0 (http://genetics.bwh.harvard.edu/pph2) and MutationTaster 1.0 algorithms 
(http://www.mutationtaster.org). SETD2 promoter was amplified using by PCR using a GC-rich 
enzyme (roche Applied Science) and the following primers: F, 5’-CGGTCTGGCCCACATCACT-3’ and 
R, 5’- ATCGGGAGCGGCTGGAGA-3’ and was sequenced separately by Sanger sequencing. 
 
4.1.6 Quantitative RT-PCR 
In the HMC-1.1 and HMC-1.2 cell lines and in the 57 samples of the validation cohort, SETD2 mRNA 
expression was assessed by quantitative RT-PCR. Total RNA (200 ng) was reverse transcribed to 
cDNA with the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). Assays 
were performed in triplicate on the ABI 7900HT system (Applied Biosystems) using pre-designed 
TaqMan Gene Expression Assays (Thermo Fisher Scientific) for SETD2 (Hs01014784_m1) and TBP 
(Hs00427621_m1) as control gene. SETD2 mRNA expression levels were quantified using the 
Comparative Ct method, using a pool of healthy donors as calibrator76.  
 
4.1.7 Methylation analysis of the SETD2 promoter 
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Methylation status at the SETD2 promoter was assessed in the validation cohort using EpiTect 
Methyl II PCR Assays (EPHS110216-1A; Qiagen) on an ABI PRISM 7900HT, according to 
manufacturer’s instructions. A methylation sensitive (EPHS115450-1A) and methylation 
dependent (EPHS115451-1A) control assay were also run for all the samples analyzed76. 
 
4.1.8 Sequencing of recurrently mutated myeloid genes 
Fifty-four genes frequently mutated in myeloid malignancies, including all those so far reported to 
be mutated in SM, were interrogated in 40 patients of the validation cohort for whom leftover 
DNA from SETD2 mutation screening was available, using the Trusight Myeloid Sequencing Panel 
(Illumina) on a MiSeq instrument (Illumina). The panel interrogated the full coding region of 15 
genes: BCOR, BCORL1, CDKN2A, CEBPA, CUX1, DNMT3A, ETV6/TEL, EZH2, KDM6A, IKZF1, PHF6, 
RAD21, RUNX1/AML1, STAG2 and ZRSR2, and exonic hotspots of 39 genes: ABL1, ASXL1, ATRX, 
BRAF, CALR, CBL, CBLB, CBLC, CSF3R, FBXW7, FLT3, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, JAK2, 
JAK3, KIT, KRAS, KMT2A/MLL, MPL, MYD88, NOTCH1, NPM1, NRAS, PDGFRA, PTEN, PTPN11, 
SETBP1, SF3B1, SMC1A, SMC3, SRSF2, TET2, TP53, U2AF1 and WT1 by 568 amplicons (length 
range: 225–275 bp). Amplicon libraries were prepared from 50 ng of DNA. Paired-end sequencing 
runs were performed on a MiSeq (Illumina, San Diego, CA) with reagent kit v3 according to 
manufacturer’s instructions. Base-calling and sequence alignment were performed using MiSeq 
reporter software. VCF files were generated using Somatic Variant Caller and uploaded to Variant 
Studio v2.1, where variants were annotated, classified, and filtered for quality, coverage, read 
depth, allelic frequency, and significance76. 
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4.1.9 Drug treatments, Aurora kinase A and mdm2 silencing 
Bortezomib (10 nM) was used as proteasome inhibitor, to evaluate if SETD2 degradation was a 
proteasome-dependent or -independent mechanism. Danusertib (500nM) was used as Aurora 
Kinase inhibitor and SP141 (5 µM) as mdm2 inhibitor. Finally, midostaurin (PKC412) 4 µM was 
used to test its ability to inhibit AKA activity in a H3K36Me3-deficient context. 
After 24 h exposure of HMC-1.1 and HMC-1.2 cells to the above mentioned drugs treatments 
apoptotic cell death was assessed by measuring the uptake of fluorescinated Annexin V and 
propidium iodide (PI, both from Roche). A FACsCantoII flow cytometer (Beckton Dickinson) set at 
488nm excitation and 530nm wavelength bandpass filter for fluorescin detection or 580nm for PI 
detection, and a dedicated software (DIVA software, Beckton Dickinson) were used for analysis.  
Drug cytotoxicity was evaluated in clonogenic assays in HMC1.1 and 1.2 cells and in primary cells 
derived from advanced SM patients. Drug specificity was evaluated using 2 healthy donors as 
control. Briefly, we evaluated the reduction of colony (generated in 0.9% methylcellulose 
supplemented with 30% fetal calf serum) number in the presence of increasing doses of 
bortezomib (0.25-1 nM) after 10-day incubation at 37°C in fully humidified atmosphere and 5% 
CO2. Nonlinear regression analyses were used to calculate the lethal dose (LD50) of the different 
drug. 
Finally, to confirm AKA and mdm2 effects on setd2 deficiency, we transiently silenced AKA and 
mdm2 expression using a short interfering RNA approach. Briefly, we transfected in HMC1 cell line 
a selected siRNA able to inhibit AKA or mdm2 expression. RT-PCR to confirm reduced expression of 
the target genes, western blotting and immunoprecipitation assays  to test silencing effects on 
setd2 were performed after 72 hrs from transfection. 
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4.1.10 Protein extraction, co-immunoprecipitation/immunoblotting and Western blotting  
HMC 1 cells or primary SM patient cells were cultured for in standard medium alone or with 4 μM 
midostaurin (c-Kit inhibitor), 10 nM bortezomib (proteasome inhibitor), 500nM danusertib (AKA 
inhibitor), 5 μM SP141 (MDM2 inhibitor), followed by lysis and boiling for 10 min in SDS-PAGE 
loading buffer. Lysates were separated on 10% Tris-glycine gels, transferred, and blotted. 
Briefly, western blotting analysis was performed using 70 μg of whole cell lysates. Co-
immunoprecipitation (IP) and Immunoblotting were performed using 250 µg of whole cell lysates 
in the presence of Cyanogen bromide (CNBr)-activated sepharose 4B (GE Healthcare) conjugated 
with an anti-setd2 antibody (Abnova) raised against a synthetic peptide corresponding to an 
internal region of human setd2 maintained in the truncated isoform. The anti-setd2 antibody was 
added to a 50% protein G-sepharose bead slurry and incubated with rotation at 4°C overnight. The 
cleared cellular lysates were added to the anti-SETD2-bound protein G-sepharose and the 
incubation continued overnight at 4°C. Proteins or IP products obtained through overnight 
incubation with primary antibodies in IP buffer (250 mM NaCl, 15 mM MgCl2, 40 mM HEPES, 60 
mM glycerophosphate supplemented with protease inhibitors) were resolved in SDS-
polyacrylamide gel electrophoresis. Gels were then transferred onto PVDF membranes  and 
labeled with primary and secondary antibodies in PBS buffer with 5% bovine serum albumin and 
0.1% Tween 20. The following primary antibodies were used for Co-IP/immunoblotting and WB: 
anti-setd2, anti-H3K36Me3, anti-RNAPol II, anti-hnRNP, anti-AKA, anti-phospho-AKA(T288), anti 
AKB, anti-phospho-AKB(T232), anti-phosphoH3(S10), anti-p53, anti-p21, anti-p27, anti-bax, and 
anti-MDM2. Beta actin and Histone H3 were used as loading control. Immunoreactive proteins 
were visualized by probing with horseradish peroxidase-conjugated secondary antibodies and then 
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by enhanced chemiluminescence (ECL, Thermo Fisher Scientific). Signal intensities in single blots 
obtained from three individual experiments were quantified with the ImageJ software. Such 
software attributes a numerical value to signals of chemiluminescent substrates, thereby allowing 
a comparative analysis of protein levels across different samples.  
4.1.11 SETD2 silencing in ROSA D816V cell line 
To investigate cellular effects of SETD2/H3K36Me3 deficiency on DNA damage and genomic 
instability, we silenced SETD2 expression using a short interfering RNA approach. Briefly, we 
transfected in ROSA D816V cell line a selected siRNA able to inhibit SETD2 expression after 9 
weeks exposure. The transfection was repeated every 4 days and SETD2 expression, both at 
transcriptional and at translational levels, was assessed by RT-PCR and WB.   
To assess the activation and proficiency of HR, control and SETD2 siRNA-depleted cells was 
challenged with DNA damaging agents (UV and doxorubicine) and chased in fresh media at regular 
timepoints afterwards (2, 4, 6, 8, 24hrs). Phosphorylated H2AX and RAD51 expression were 
assessed by WB. Moreover P-H2AX and RAD51 foci as surrogate markers of active HR were 
evaluated by immunofluorescence (IF). An empty vector was transfected in Rosa cells and used as 
a negative control.  
 
4.1.12 Immunofluorescence (IF) analyses  
Cells set on poly-L-lysine-coated glass slides were fixed with 3% paraformaldehyde for 10’ at 37°C, 
washed with 0.1M glycine in phosphate-buffered saline (PBS), permeabilized in 70% ice-cold 
ethanol for 2’ at -20° C and incubated overnight at 4°C with primary anti-ɤH2AX antibody and anti 
RAD51 antibodies. Slides were then stained with a secondary anti-rabbit antibody conjugated with 
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Alexa Fluor 568 for 2 h at room temperature and a subsequent anti-mouse antibody 
fluoresceinated. 6-diamidino-2-phenylindole (DAPI) was used to stain the nuclear compartment. IF 
analyses were performed using an Axiovert 40 CFL microscope (Zeiss). Images were acquired with 
a 100X objective and analyzed with the AxioVision software. 
4.1.13 Statistical analysis 
Analysis of variance followed by Tukey post-hoc test was applied in order to detect differences in 
SETD2 and H3K36Me3 expression between groups. Statistical analysis were carried out by R.15 
Spearman correlation index was calculated between SETD2 and H3K36Me3 level and disease 
subtype.  
 
4.2 AIM2: Clinical implication of SETD2 inactivation in SM 
4.2.1 Samples 
A total of 88 SM patients were included in this part of the study. We prospectively added to our 
historical cohort (57 patients) the newly diagnosed patients with ISM from the participating 
centers (Azienda Ospedaliera Universitaria Integrata, Verona; IRCCS Policlinico San Matteo 
Foundation, Pavia; University of Bologna; IRCCS Ca' Granda Ospedale Maggiore Policlinico 
Foundation and University of Milan; Azienda Unità Sanitaria Locale, Romagna), with the intent to 
extend the group of the “non advanced” form, that we supposed having normal level of SETD2 and 
normal H3K36Me3. The diagnosis were: ISM (n=44), SSM (n=5), SM-AHN (n= 10), including  ISM-
AHN (n=2, one associated with indolent non Hodgkin Lymphoma and one with 
myelodisplastic/myeloproliferative neoplasm unclassified), ASM-AHN (n=5 , two cases associated 
with Myelomonocytic leukemia, two cases associated with myelodisplastic syndrome, and one 
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Acute myeloid leukemia), MCL-AHN (n=3,  two cases associated with a  myelodisplastic syndrome 
and one with Acute Myeloid leukemia), ASM (n=17), MCL(n=12).  
All the data collected refer to the time of diagnosis, prior to any therapy performed.  
4.2.2 Diagnosis 
Diagnosis of systemic mastocytosis was based on the World Health Organization (WHO 2016) 
diagnostic criteria, and it was established when the major plus one minor criterion, or three minor 
criteria, were satisfied. All the patients were studied with bone marrow smears cytology, BM 
biopsy with immunohistochemistry staining for tryptase; serum tryptase levels; analysis of 
CD2/CD25 expression on mast cells by flow or immunohistochemistry ; genotyping of cKIT (D816V) 
mutation. Bone marrow biopsies were evaluated by local pathologist. Analysis for mutations in KIT 
were performed with reverse transcriptase polymerase chain reaction (RT-PCR) restriction 
fragment length polymorphism (RFLP) analysis , allele-specific ARMS-RT-qPCR, D-HPLC analysis 
followed by Sanger sequencing, direct Sanger sequencing, and/or Digital PCR  according to 
center’s policy.  
The diagnosis of SSM was based on the presence of two or more “B” findings, that include BM 
biopsy showing >30% mast cell infiltration and/or serum tryptase >200 ng/mL; signs of dysplasia or 
myeloproliferation in non-mast cell lineages with normal blood counts; hepatomegaly without 
impairment of liver function, and/or splenomegaly without hypersplenism, and/or 
lymphadenopathy on palpation or imaging.  The diagnosis of ASM was based on the presence of 
one or more C-findings (cytopenia with an absolute neutrophil count <1 × 109 /l, hemoglobin <10 
g/dl, platelets <100 × 109 /l, hepatomegaly with impaired liver function, palpable splenomegaly 
with signs of hypersplenism, malabsorption with significant hypoalbuminemia and/or significant 
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weight loss >10% over the past 6 months)14,29. Diagnosis of MCL was based on the presence of at 
least 20% MC in BM smears with or without C-findings. The diagnosis AHNMD was established by 
evaluating peripheral blood (for example, monocytosis, basophilia and/or eosinophilia, left shift 
and/or a prominence of myelocytes) and bone marrow smears by morphology, histology and 
immunohistochemistry using WHO criteria and a panel of standard markers, depending on the 
suspected AHN subtype.  
 
4.2.3 Laboratory studies 
D816V KIT mutation was evaluated locally according to center’s policy, only selected cases that 
were negative were repeated with more sensitive Digital-PCR.  
Setd2 and H3K36Me3 values were obtained by WB analysis, as previously described.  
 
4.2.4 Clinical data 
The clinical baseline characteristics we collected were: age, sex, diagnosis as for WHO2016, Hb 
(g/dL), WBC (x 109), platelets (x 109), serum tryptase level (ug/L), presence of skin lesions, 
presence of mediator related sympthoms (including pruritus, flushing, urticaria and angioedema; 
gastrointestinal, including diarrhea,  nausea and vomiting; muscular pain; headache and dizziness, 
hypotension), history of severe allergic/anaphylactic episodes, palpable splenomegaly, presence of 
osteoporosis or osteopenia, serum alkaline phosphatase [ALP] (U/L), lactate dehydrogenase [LDH] 
(U/L), expression value of SETD2 protein and H3K36Me3. 
All patients were studied for B and C findings using appropriate laboratory tests and ultrasound or 
CT scan. Osteoporosis was assessed by bone mineral density of lumbar spine and femur with Dual-
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energy X-ray absorptiometry (DEXA) technique and defined as T score <-2.5 in at least one site. 
Osteosclerosis, fractures and lytic lesions were assessed with x-ray of skeleton or spine and pelvis, 
at minimum.  
4.2.5 Statistical Analysis 
All statistical analyses considered clinical and laboratory parameters obtained at the time of 
diagnosis or first referral to clinical care center, which, in most instances, coincided with time of 
BM biopsy and study sample collection. We summarized data by using mean ± standard deviation 
(SD) or median and range, as appropriate, for continuous variables and absolute frequencies and 
percentages for categorical variables. 
Chi-square or Fisher’s Exact test were used, as appropriate, for comparisons between categorical 
variables whereas the Student t-test or Wilcoxon rank-sum test were used for comparisons 
between a binary and continuous variable. In case of more than two categories the F test or the 
Kruskal Wallis test were used.   
Correlation among variables was assessed using using Pearson correlation coefficients or the 
tetrachoric ones. 
The identification of the cutoff for the expression of SETD2/H3K36me3 separating ISM from the 
other WHO subtypes was evaluated using receiver operating characteristic (ROC) and the Youden 
index criteria.  
Overall survival (OS) was defined as the time since date of diagnosis to date of death from any 
cause and last visit. The Kaplan–Meier (KM) method and log-rank test were used to compare OS 
between groups of patients. Hazard ratios (HRs) and 95% confidence intervals (CIs) were 
estimated by means of the Cox proportional hazards regression model. The proportional hazard 
assumption was assessed graphically and through the test based on Schoenfeld residuals. 
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Multivariable survival analysis was performed using a stepwise forward algorithm for variable 
selection (the nominal value for variable selection was set to 0.10). Nevertheless, the set of 
candidate variables to consider for multivariable analysis took into account the results from the 
correlation analysis among variables and the knowledge (from the pertinent literature) about the 
prognostic significance of certain clinical and laboratory variables. 
All statistical tests were two-sided, with P < 0.05 considered as statistically significant where not 
otherwise specified. 
 All statistical analyses were performed using STATA 15.1 statistical software (StataCorp, College 
Station, TX, USA) or with R, version 3.4 (R Core Team: Vienna, Austria). 
 
5. RESULTS 
5.1 AIM 1: Characterization of mechanisms involved in SETD2 down-modulation in SM 
5.1.1 SETD2 and H3K36Me3 deficiency are recurrent events in SM and cluster in advanced disease 
To investigate the frequency of SETD2 inactivation in a relatively large cohort of SM patients, we 
used a western blotting approach to assess H3K36Me3 levels as a surrogate marker of loss of 
SETD2 function and to screen for the expression of SETD2 full-length vs truncated isoforms. No 
evidence of abnormal isoforms was found. However, the SETD2 protein turned out to be reduced 
or not at all expressed in the great majority of patients examined (Figure 7). H3K36Me3 paralleled 
SETD2 expression and was reduced or absent accordingly (Figure 7). In one MCL, one ASM and two 
ISM patients, SETD2 and H3K36Me3 levels were assessed in total MNC fractions obtained from BM 




Figure 7:  SETD2 protein and H3K36Me3 deficiency in SM: WB results for SETD2 protein and 
H3K36Me3 levels in SM patients as compared to a pool of healthy donors (HDs) 
 
To confirm western blotting results, IHC with an anti-SETD2 antibody was performed on BM 
trephine biopsies of patients displaying various SETD2 protein levels. The intensity of nuclear 
staining and the percentage of immunostained atypical MCs varied among the cases and were 
consistent with SETD2 protein expression as assessed by western blotting (Figure 8). Internal 
positive controls (BM myeloid precursors and megakaryocytes) were present in each case and 
confirmed the specificity of the stain.  
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Figure 8. IHC with anti-SETD2 antibody. 400x magnification. (A)patient ISM16 (SETD2 
expression=0.926 by Western blotting). Densely packed aggregates of spindle-shaped MCs 
surrounded by reactive lymphocytes show diffuse and intense nuclear staining for SETD2. (B-D) 
patient ISM15 (SETD2 expression=0 by Western blotting), patient SSM1 (SETD2 expression=0 by 
Western blotting) and patient MCL10 (SETD2 expression=0.25 by Western blotting) show markedly 
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reduced intensity of staining and reduced percentage of positive atypical MCs; (E)SETD2 expression 
in normal BM myeloid precursors, megakaryocytes and sinusoidal endothelia; (F) chronic 
myelomonocytic leukemia showing intense SETD2 positivity in both myelo-monocytic components 
and megakaryocytes. 
 
Median SETD2 and H3K36Me3 levels, assessed by densitometric analysis of western blotting 
results were significantly correlated with each other (Spearman R = 0.91, P<0.001) and were lower 
in advanced SM (R = 0.57, P<0.001) (Figure 9). In particular, patients with MCL and ASM displayed 
significantly lower levels of SETD2 and H3K36Me3 as compared to ISM (SETD2: P = <0.001 and P = 
0.002, respectively; H3K36Me3: P 0.001 and P = 0.004, respectively).  
 
 
Figure 9. Box and whiskers plots of SETD2 and H3K36Me3 level estimates obtained by 
densitometric analysis of western blots. 
 
There seemed to be no differences in SETD2 expression between advanced SM patients with (n = 
8) or without (n = 26) AHN. There seemed to be no preferential association between SETD2 loss of 
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function and the presence or absence of specific additional mutations or mutation patterns in 
myeloid genes (for example, SF3B1, SRSF2, TET2, ASXL1 and so on; Table 6). 
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      SETD2 level KIT mutation Additional mutated genes 
1 MCL2 MCL 0 D816H PTPN11 
2 MCL3 MCL 0 S476I none 
3 MCL4 MCL 0 D816V RUNX1; TET2; PHF6 
4 MCL5 MCL 0 D816V NA 
5 MCL6 MCL 0 none NA 
6 MCL7 MCL 0 D816V SF3B1 
7 MCL8 MCL 0 none SF3B1; NRAS; IKZF1 
8 MCL9 MCL 0.421 none SF3B1; TET2; MLL 
9 MCL10 MCL 0.25 none NA 
10 MCL11 MCL-AHN 0 D816H SRSF2 
11 MCL12 MCL-AHN 0 D816V NA 
12 ASM1 ASM 0 D816V NA 
13 ASM2 ASM 0 D816V SRSF2 
14 ASM3 ASM 0.594 D816V NA 
15 ASM4 ASM 0.704 D816V ASXL1; NRAS; BCORL1 
16 ASM5 ASM 0 D816V none 
17 ASM6 ASM 0.621 D816V RUNX1; ASXL1 
18 ASM7 ASM 0 D816V NA 
19 ASM8 ASM 0.299 D816V none 
20 ASM9 ASM 0.554 D816V DNMT3A 
21 ASM10 ASM 0.552 D816V CBL 
22 ASM11 ASM 0.594 D816V none 
23 ASM12 ASM 0.364 D816V NA 
24 ASM13 ASM 0.254 D816V TET2; NRAS 
25 ASM14 ASM 0 D816V NA 
26 ASM15 ASM 0 D816V NA 
27 ASM16 ASM 0 D816V none 
28 ASM17 ASM 0 D816V SRSF2; TET2 
29 ASM18 ASM-AHN 0.191 D816V SF3B1; ASXL1 
30 ASM19 ASM-AHN 0 D816V ASXL1; SRSF2 
31 ASM20 ASM-AHN 0 D816V GATA2 
32 SSM1 SSM 0 D816V NA 
33 SSM2 SSM 0.091 D816V NA 
34 SSM3 SSM 0.243 D816V NA 
35 ISM1 ISM 0.675 D816V none 
36 ISM2 ISM 0.561 D816V none 
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37 ISM3 ISM 0.323 D816V none 
38 ISM4 ISM 0 D816V none 
39 ISM5 ISM 0 D816V none 
40 ISM6 ISM 0.437 D816V NA 
41 ISM7 ISM 0.496 D816V NA 
42 ISM8 ISM 0.521 D816V none 
43 ISM9 ISM 0.425 D816V NA 
44 ISM10 ISM 0.452 D816V NA 
45 ISM11 ISM 0.774 D816V none 
46 ISM12 ISM 0.668 D816V none 
47 ISM13 ISM 0.758 none none 
48 ISM14 ISM 0.905 D816V none 
49 ISM15 ISM 0 none none 
50 ISM16 ISM 0.924 D816V none 
51 ISM17 ISM 0.815 none none 
52 ISM18 ISM 0.918 D816V ASXL1 
53 ISM19 ISM 1 D816V none 
54 ISM20 ISM 0.815 D816V none 
55 ISM21 SM-AHN 0 D816V none 
56 ISM22 SM-AHN 0.542 D816V CBL 
57 ISM23 SM-AHN 0.998 none U2AF1 
 
Table 6. Mutated genes additional to KIT in the patients of the validation cohort (NGS-Trusight 
Myeloid Sequencing Panel). The index MCL case (MCL), for whom WES data were available, was 
negative for mutations in any of the 54 genes of the panel. NA, not available. 
 
5.1.2 SETD2 loss of function in SM occurs at the post-translational level  
The screening for mutations of SETD2 gene by Sanger sequencing conducted on 11 MCL cases and 
the application of a high throughput approach (My Seq Instrument) on the remaining 46 samples 
of the validation cohort excluded the presence of SETD2 mutations.  
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Deletions of the 3p21.3 region are a frequent and early event in the formation of lung, breast, 
kidney and other cancers78, and the human SETD2 gene is located at the cytogenetic band p21.31, 
so the first attempt to explain its loss of function consisted to verify the LOH at this level. We thus 
examined the copy number status and searched for LOH at 3p21 in 13 cases of the validation 
cohort (eight MCL, four ASM, one ISM) thus extended the screen for LOH specifically at 3p21.3 in 
the remaining patients of the validation cohort.  Overall, LOH was detected in 27/57 (47%) SM 
patients, namely in 8/11 (72%) MCL-, 11/20 (55%) ASM-, 1/3 SSM- and 7/23 (30%) ISM patients, 
but the patients with evidence of LOH at 3p21.3 did not always harbor lower SETD2 protein levels 
as compared to patients with no LOH. Thus, the biological significance of the recurrent 3p21.3 LOH 
events that can be observed in SM remains, at present, unclear. 
We then assessed whether promoter hyper-methylation might be responsible for SETD2 protein 
deficiency, in the presence or absence of LOH. Analysis of the SETD2 promoter showed <1% 
methylated DNA in all the patients of the validation cohort. Methylation levels were not different 
from those of healthy donors. Other mechanisms of transcriptional down-regulation were 
excluded, since SETD2 mRNA levels were not significantly lower in the validation cohort as 
compared to healthy donors. To rule out the possibility that SETD2 loss of function might be 
another age-associated alteration in an epigenetic regulator, 80 healthy older adults with an age 
ranging from 65 to 95 years were screened for SETD2 mutations and for alterations in SETD2 
protein expression or H3K36Me379-81. No sequence variants other than the Pro1962Leu and the 
Asn1155Asn SNPs were detected. All the older adults did express SETD2; and densitometric 
analysis of western blots (done using a pool of 10 younger adults with an age ranging from 20 to 
30 years as a calibrator, after having excluded inter-individual variations of expression) showed 
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comparable SETD2 and H3K36Me3 levels among individual older adults as well as between older 
and younger adults (Table 7). 
 
 
N Age SETD2 level H3K36Me3 level 
1 65 1.121 0.996 
2 65 1.248 1.077 
3 65 0.997 0.999 
4 65 1.173 1.073 
5 65 1.174 0.962 
6 65 1.233 1.117 
7 65 0.999 0.887 
8 66 1.101 1.211 
9 66 1.049 1 
10 66 1.013 1.022 
11 67 1.154 1.103 
12 67 0.911 1.199 
13 67 1.003 1.000 
14 67 0.799 0.998 
15 67 1.150 1.296 
16 67 0.800 0.800 
17 68 1.023 1.058 
18 68 0.983 1.015 
19 68 0.816 0.897 
20 69 0.974 1.141 
21 69 0.832 1.099 
22 69 1.222 1.117 
23 70 1.245 1.267 
24 70 1.005 1.000 
25 70 0.804 0.799 
26 71 0.888 0.896 
27 71 0.941 0.888 
28 71 1.111 0.975 
29 71 1.211 0.969 
30 72 1.115 1.210 
31 72 1.256 1.201 
32 73 1.000 0.921 
33 73 0.822 0.799 
34 73 1.101 1.122 
35 74 0.887 0.799 
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36 74 0.955 0.888 
37 74 0.876 0.850 
38 74 0.9 0.9 
39 74 0.966 0.899 
40 74 1.120 1.010 
41 75 1.222 1.000 
42 75 1.111 1.144 
43 75 1.265 1.201 
44 75 0.944 0.886 
45 76 1.246 1.001 
46 76 1.000 0.969 
47 76 1.268 1.010 
48 76 0.879 0.856 
49 77 1.203 1.151 
50 77 1.040 0.998 
51 77 0.832 0.819 
52 78 1.000 1.000 
53 78 1.200 1.210 
54 78 1.215 1.110 
55 78 0.904 0.799 
56 78 0.888 0.996 
57 79 0.841 0.8 
58 79 1.000 0.966 
59 80 1.115 1.000 
60 80 1.122 1.100 
61 81 1.133 1.000 
62 81 1.200 1.200 
63 81 0.885 0.885 
64 82 0.876 0.821 
65 83 0.999 0.990 
66 83 0.991 0.991 
67 84 0.955 0.915 
68 84 1 1 
69 84 1.230 1.244 
70 84 1.001 1.000 
71 85 1.224 1.004 
72 86 1.155 1.113 
73 86 0.852 0.850 
74 87 1.178 1.111 
75 87 1.009 0.877 
76 88 1.124 1.100 
77 90 0.898 0.896 
78 91 0.910 0.899 
79 93 0.996 0.888 
80 95 1.100 1.000 
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Table 7.  SETD2 and H3K36Me3 levels in 80 healthy older adults with an age ranging from 65 to 95 
years. Expression was assessed by densitometric analysis of Western blots. 
 
5.1.3 Characterization of HMC.1 and ROSA cell lines as “in vitro” models  
SETD2 expression levels and activity were assessed in HMC-1 and ROSA cell lines by western 
blotting assay. Both HMC-1.1 and 1.2 clones displayed SETD2 and H3K36Me3 deficiency as our 
cohort of patients with advSM (Figure 10), while ROSA expressing KIT WT or mutated (D816V) 
showed SETD2 expression levels and activity superimposable to those of healthy donors (data not 
shown). Sequencing ruled out the presence of SETD2 gene mutations. Similarly to the patients of 
the validation cohort, both HMC-1.1 and HMC-1.2 cells were found to have no significant 
reduction in SETD2 transcript levels as compared to SETD2 wild-type cell lines and the gene 
promoter was found to have very low methylation levels (4.08% and 1.08% in HMC-1.1 and HMC-
1.2, respectively). This suggested that similar mechanism(s) acting at the translational or post 




Figura 10: SETD2 protein and H3K36Me3 levels in HMC-1.1 and -1.2 cell lines 
 
5.1.4 SETD2 deficiency results from enhanced proteasomal degradation 
Once all the mechanisms of altered transcription were excluded, we proceed to investigate 
whether this down-modulation could be the result of an increased degradation of the protein. In 
HMC-1 cells, incubation with the proteasome inhibitor bortezomib at a concentration of 10 nM for 
24 h, rescued SETD2 protein expression and restored H3K36Me3 levels (Figure 11), indicating that 
a functional SETD2 protein is regularly translated in neoplastic MCs, and that failure to detect it by 




Figura 11. SETD2 protein and H3K36Me3 levels in HMC-1.1 and -1.2 cell lines before and 
after inhibition of proteasome-mediated degradation by bortezomib 
 
To investigate the post-translational modifications underlying the altered turnover of the setd2 
protein, after Bortezomib treatment, SETD2 was immunoprecipitated with a specific antibody able 
to recognize it and the immune-complex, loaded on gel and transferred onto a PVDF filter, it has 
been labeled with antibodies able to recognize the sumoylated and ubiquitinated epitopes of the 
protein. The results showed a protein accumulation in the sumoilated and ubiquitinated form of 
SETD2 protein, thus confirming the hypothesis that its down-modulation is mediated by instability 
mechanisms due to a dysregulation of the post-translational modifications. We therefore 
speculated that reduced or undetectable SETD2 expression in advanced SM patients might be 
accounted for by hyper-ubiquitination and -SUMOylation leading to proteasomal degradation 




Figure 12. Ubiquitinated and SUMOylated SETD2 after proteasome inhibition by bortezomib 
in HMC-1 cells 
 
We thus compared the effects of proteasome inhibition in malignant MCs from advanced SM 
patients displaying no SETD2 protein and from ISM patients with near-normal SETD2 levels. In 
contrast to SETD2-deficient patients, where results were superimposable to those obtained in 
HMC-1 cells, patients with near-normal SETD2 expression had similar levels of ubiquitinated and 
SUMOylated SETD2 protein (and similar H3K36Me3 levels) before and after the inhibition of 




Figure 13.  Co-immunoprecipitation  with an anti-SETD2 antibody and immunoblotting 
(western blotting) with anti-ubiquitin and anti-SUMO antibodies performed before and after 
bortezomib treatment (10 nM for 24 h)in two ISM patients and one MCL patient. 
 
Given the ability of bortezomib to rescue setd2 expression and H3K36Me3, we tested whether 
proteasome inhibition might be effective in vitro in HMC-1 cells. Bortezomib as single agent 
strikingly inhibited colony formation (LD50 in HMC-1.1 = 0.173 nM; LD50 in HMC-1.2 = 0.226 
nM)(Figure 14).  
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Figure 14. Reduction of clonogenic growth in HMC-1.1 cells  (red curve) and -1.2 cells (blue 
curve), in the presence of increasing doses of bortezomib (0.25–1 nM) used as single agent 
 
Moreover bortezomib reduce the clonogenic potential of setd2/H3K36Me3-deficient neoplastic 
MCs from two patients with MCL with no SETD2 expression (MCL3 and MCL7) and one patient 
with ASM (ASM18) with very low SETD2 expression (20% as compared to a pool of healthy 
donors). Bortezomib induced a marked dose dependent reduction in colony formation with LD50 
ranging from 0.105 to 0.295 nM (Figure 15).  
 
Figure 15.Growth inhibition curves and LD50 values after Bortezomib treatment in cell 
 
5.1.5 Aurora Kinase A (AKA) and MDM2-mediated post-translational modifications contribute to 
SETD2 non genomic loss of function in Advanced SM  
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To investigate which were post-translational modifications  affecting setd2 stability, we used an 
“in silico” approach and interrogated on-line databases  (BioGRID) to identify candidate proteins 
with ubiquitin-ligase activity that could bind SETD2 and address it to proteasomal degradation. We 
found that SETD2 may bind the oncogene MDM2, which encodes an E3 ubiquitin ligase 
overexpressed in solid cancers (pancreatic cancer). We confirmed this observation through co-
immunoprecipitation experiments after proteasome inhibition on HMC-1.1 and HMC-1.2 cells 
(Figure 16). Setd2 co-immunoprecipitation with MDM2 supported the interaction between the 




Figure 16. After proteasome inhibition SETD2 levels restored and the interaction SETD2-MDM2 is 
revealed.   
 
 
To confirm our hypothesis, treatments with the MDM2 inhibitor SP-141  were performed: mdm2 
inhibition rescued SETD2 expression and H3K36Me3, suggesting that mdm2 may play a role in 
SETD2 degradation in our in vitro models (Figure 17)82. Moreover, SP-141 treatment of HMC-1 
cells at micromolar doses induced cytostatic but not cytotoxic effects as shown by cell growth 
curves. Clonogenic assays supported the cytostatic effects of SP141 in HMC-1.1 and -1.2 cells 
(Figure 18, 19). siRNA-mediated knock-down of MDM2 also rescued SETD2 expression and activity, 
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further supporting the hypothesis that SETD2 hyper-ubiquitination by MDM2 plays a role in SETD2 




Figure 17. Treatment of HMC-1.1 and HMC-1.2 with SP-141induce the restoration of normal SETD2 













Figure 19. Dose-survival curves of HMC 1.2 cell line treated with increasing dose of SP141 ( 96 h). 
Starting from the evidence that mdm2 inhibition did not result in cytotoxic effects we performed 
further in silico research to identify other possible setd2 ligands involved in its loss of stability.  
 
The BioGRID database predicts that Aurora kinase A may also physically interact with SETD2. 
Accordingly, we found that activated Aurora A co-immunoprecipitates with SETD2 in the HMC-1 
cell line after proteasome inhibition (Figure 20). We also found that Aurora A is aberrantly 
expressed and activated in advanced SM and this inversely correlates with setd2 expression 
(Figure 21). Both inhibition of kinase activity with Danusertib and down-modulation by siRNA 
rescued SETD2 expression (Figure 22). Taken together, these data suggest that phosphorylation by 
aberrantly expressed Aurora A may be one of the triggers of MDM-2 dependent SETD2 
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degradation and point to several druggable targets that are worth exploring in an attempt to 
rescue SETD2 expression.  
 
 













              % APOPTOSI          5,0%      60,1%         3,5%         65,5% 
 
Figure 22. Aurora A inhibition by danusertib correlates with Ser/thr unphoshorylated setd2 
re-expression in HMC-1 cells..    
 
5.1.6 Setd2 non genomic loss of function induced p53 degradation, cell cycle and apoptosis 
deregulation 
p53 is a transcription factor that plays a pivotal role in tumor suppression by directing cellular 
responses to diverse stresses including DNA damage and oncogene activation resulting in diverse 
biological effects. The wide range of p53's biological effects can in part be explained by its 
activation of expression of a number of target genes83,84. MDM2, a major ubiquitin E3 ligase for 
p53 and also the target of p53, plays an important role in down-regulating p53 activities. Recently, 
increasing amounts of data suggest that p53 stability and degradation are more complex than 
once thought85. 
 70 
In the present study, we identified SETD2 as an interacting protein of p53 in vitro through co-
immunoprecipitation assay. SETD2 enhances the transcriptional activity of p53 and regulates 
expression of select p53 target genes. We also demonstrate that loss of SETD2 may affect the 
stability of p53 protein, by contrast rescue of SETD2 after proteasomal inhibition stabilized p53 
and activated its target genes transcription (Figure 23). 
In particular in HMC-1 cell line we confirmed what has been already reported in ccRCCs, p53 co-
immunoprecipitates with setd2 after proteasome inhibition. Moreover, we observed that rescuing 
the interaction between setd2 and p53 with bortezomib stabilized p53 and up-regulated a subset 
of p53 targets including p21, p27, Bax and Gadd45a (Fig. 23). This restored inhibition of cell 










5.1.7 Loss of SETD2 and H3K36Me3 is associated with increased DNA damage 
Recent studies have established a role for SETD2 and H3K36 trimethylation in HR repair of double 
strand breaks (DSBs) in human cells (Pfister, Cell Rep 2014; Carvalho, Elife 2014). SETD2 was found 
to promote the formation of Rad51 foci, and SETD2 depletion generated a mutation signature with 
significantly increased deletions arising through microhomology-mediated end-joining. To 
investigate whether increased DNA damage and reduced HR proficiency can be observed also in 
SETD2/H3K36Me3-deficient SM, we used immunofluorescence to assess phosphorylated histone 
2A.X (H2AX), which marks ongoing DNA damage signalling and DNA DSBs (Lukas, Nat Cell Biol 
2011) and Rad51, which we used as a surrogate for active HR. With respect to cells from healthy 
controls, cells from SETD2- and H3K36Me3-deficient patients had significantly higher levels of 
H2AX (Figure 24). However, Rad51 levels in MCL cells were comparable to those of controls, 
suggesting the possibility that in SETD2/H3K36Me3-deficient SM enhanced DNA damage may less 




Figure 24. Immunofluorescence analysis of H2AX phosphorilation (green) and Rad51 (red) 
expression in mononuclear cells from a HD, an ISM patient and two MCL patients. Nuclei were 
marked with DAPI (Blue).  
 
Next, to correlate setd2 loss of function and genomic instability in SM the ROSAD816V cell line was 
used as in vitro model. ROSAD816V cells display SETD2 and H3K36me3 levels superimposable to 
healthy donors, therefore were studied by WB and IF to assess γH2AX and Rad51 in steady state 
and after sub-lethal DNA damage by UV exposure. The same experiments were carried out after 
SETD2 silencing for 2 months. Cells with silenced SETD2 had significantly higher levels of γH2AX 

















Figure 25. Western blotting and immunofluorescence analysis of H2AX phosphorilation (green) and 
Rad51 (red) expression in parental ROSAD816V cell line and after setd2 silencing. Nuclei were 
marked with DAPI (Blue).  
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5.1.8 Effects of midostaurin on MCs 
On the basis of the observation that hyper-phosphorylation of Aurora Kinasi A in the advanced 
forms of SM and aware of the effects of the inhibitors on the cell lines tested in vitro, we decided 
to investigate the possibility of testing Midostaurin (PKC 412), in the same experimental setting. 
Midostaurin is a pan-inhibitor that has among its molecular targets: KIT (both wild-type and 
mutated D816V), FLT3, PDGFRA and PDGFRB, IGF1R, LYN, PDPK1, RET, SYK, TRKA, VEGFR2, and 
also AKA and AKB41.  
Therefore we investigated if midostaurin effects may be addressed to AKA inhibition and 
consequent SETD2/H3K36me3 rescue. To this purpose, HMC-1 cells were treated with 5 µM 
midostaurin for 24 h and AKA, SETD2 and H3K36me3 expression were evaluated by western 
blotting (Figure 26). Treatment with midostaurin was able to inhibit AKA activity by about 60%, 
partially restoring SETD2 expression and H3K36Me3. Moreover, midostaurin treatment of HMC-1 
cells at micromolar doses induced cytostatic but not cytotoxic effects as shown by cell growth 
curves performed in liquid medium (Figure 27). 
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Figure 26. Western blotting, immunoprecipitation and co-immunoprecipitation after Midostaurin 






Figure 27: Dose-survival curves of HMC 1.1 and 1.2  cell lines treated with increasing dose of 
Midostaurin. 
Our results suggest that AKA-mediated post-translational modifications contribute to SETD2 non-
genomic loss of function in advSM. Inhibiting AKA and c-Kit activity by Midostaurin is a promising 
therapeutic strategy in patients with SETD2/H3K36Me3 deficiency.  
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Finally, our observations in cell lines were confirmed in neoplastic mast cells collected from three 
patients with advSM before and after three months of midostaurin treatment. Western blotting 




Figure 28. WB pre and post Midostaurin therapy in SM patients 
 
5.2 AIM2: Clinical implication of SETD2 inactivation in SM 
5.2.1 Patients and characteristics 
The study included 88 patients with a median age of 58 years (range 19-78). The diagnosis were: 
ISM (n=44), SSM (n=5), SM-AHN (n= 10), including  ISM-AHN (n=2, one associated with indolent 
non Hodgkin Lymphoma and one with myelodisplastic/myeloproliferative neoplasm unclassified), 
ASM-AHN (n=5 , two cases associated with Myelomonocytic leukemia, two cases associated with 
myelodisplastic syndrome, and one Acute myeloid leukemia), MCL-AHN (n=3,  two cases 
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associated with a  myelodisplastic syndrome and one with Acute Myeloid leukemia), ASM (n=17), 
MCL(n=12).  
In the entire cohort, 56.3% were males, mostly represented in ISMs, as reported in [5, 16]. Median 
age at diagnosis was 58 years (range 19-78) and it was lower (50 years) in the ISMs group 
compared with all other subtypes (p<0.001). Clinically, in the entire cohort skin lesions were 
present in 48.9% of patients, with a higher prevalence among ISM and SSM subtypes (p< 0.001) 
whereas severe anaphylaxis reactions in 34.1%, again with higher percentages among ISM and 
SSM (p<0.001). Other mediator-related or systemic symptoms were present in 62.5%, with no 
significant association with WHO subtypes (p=0.153); osteoporosis was reported in 37.1% and 
osteopenia in 71.0%, without significant association with any WHO subtypes (p = 0.203 and p= 
0.282 respectively); palpable splenomegaly  in 29.1% with a very low prevalence (2.3%) in ISM 
subtype compared to the other WHO subtypes. Anemia defined by hemoglobin < 10 g/dL was 
present in 19.5% whereas platelet count below the limit of 100 x 109/L in 19.5%. For both these 
variables prevalence was particularly low for the ISM and the SSM WHO subtypes (p<0.001). No 
statistically significant differences were observed among the subtypes for WBC and Eosinophils 
count (p=0.199 and p=0.203); serum alkaline phosphatase (ALP) above the upper normal limit of 
the reference range (> 104 U/L) in 38.1%, with association with WHO subtype (p<0.001; different  
lactate dehydrogenase [LDH]value (U/L) resulted associated with WHO categories (p=0.035);  
serum tryptase level >200 ug/L was present in 21.8%, whereas serum tryptase level > 20 ug/L in 
79.3% of patients, with lower levels in ISM compared to the other forms (p<0.001 and p=0.003 
respectively). Table 8 lists clinical and laboratory characteristics at SM diagnosis. 
 78 
The D816V KIT mutation result present in 81/88 patients. Four MCL resulted negative, and in 3 
patients a diffrent mutation was detected: D816H in two patients ( 1 MCL and 1 SM.AHN), and 
mutation S476 in MCL.   
Cytoreductive treatment in 30/37 patients with advSM included midostaurin (n = 9), cladribine (n 
= 6), cladribine following midostaurin or vice versa (n = 4), dasatinib (n = 3) or cladribine (n = 2) 
followed by intensive chemotherapy with (n = 1) or without (n = 4) allogeneic stem cell 
transplantation. Ten patients were treated with hydroxyurea (n = 2), imatinib then dasatinib (n=1), 

















 n % n % n % n % n % n %  
Gender              
F               42 47.7 10 58.8 18 40.9 7 58.3 4 80.0 3 30.0 0.257 
M 46 52.3 7 41.2 26 59.1 5 41.7 1 20.0 7 70.0  
Age (years): median 
(min-max) 58 (19 – 78) 
63 (30-77) 50 (19-72) 64 (32-78) 61 (57-65) 69             
(55-76) 
<0.001 
≤ 65 68 77.3 11 64.7 42 95.5 7 58.3 5 100.0 3 30.0 <0.001 




 13.4 (6.7 – 17.5) 
11.7 (8.3-14.0) 14.5 (9.3-17.5) 10.1 (7.7-15.6) 12.5    (12.0-
14.8) 
10.3     
(6.7-16.5) 
<0.001 
≥ 10 70 80.5 
11 68.8 43 97.
7 
6 50.0 5 100.0 5 50.0 <0.001 
< 10 17 19.5 5 31.3 1 2.3 6 50.0 0 0.0 5 50.0  







6.2                                      
(1.9 – 76.0) 
7.9                (3.4-
21.6) 
5.8                 
(3.0-76.0) 
4.6              (2.9-
54.6) 
7.6              
(4.7-9.1) 
8.1      
(1.9-63.9) 
0.199 





 227.0 (13.0 – 979.0) 
166.5 (42-470) 249 (113-366) 182 (53-464) 245      (208-
355) 
132      
(13-979) 
0.001 
≥ 100 70 80.5 9 56.3 44 100.0 7 58.3 5 100.0 5 50.0 <0.001 
< 100 17 19.5 7 43.8 0 0.0 5 41.7 0 0.0 5 50.0  




52                                (4.7 
– 2250.0) 
200                 (26-
1900) 
28.6           (4.7-
94.8) 
287            
(30.8-2250) 
140        
(18.8-250) 
115      
(14-1310) 
<0.001 
≤ 200 68 78.2 10 58.8 43 97.7 5 45.5 3 60.0 7 70.0 <0.001 
> 200 19 21.8 7 41.2 1 2.3 6 54.5 2 40.0 3 30.0  
Serum tryptase (ug/L)
†
              
< 20 18 20.7 0 0.0 16 36.4 0 0.0 1 20.0 1 10.0 0.003 
≥ 20 69 79.3 17 100.0 28 63.6 11 100.0 4 80.0 9 90.0  
Skin lesions              
No 45 51.1 11 64.7 14 31.8 10 83.3 2 40.0 8 80.0 0.002 
Yes 43 48.9 6 35.3 30 68.2 2 16.7 3 60.0 2 20.0  
Mast cell mediator 
symptoms   
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No 33 37.5 3 17.7 22 50.0 4 33.3 1 20.0 3 30.0 0.153 
Yes 55 62.5 14 82.3 22 50.0 8 66.7 4 80.0 7 70.0  
Severe anaphylaxis 
reactions   
           
No 58 65.9 17 100.0 19 43.2 11 91.7 2 40.0 9 90.0 <0.001 
Yes 30 34.1 0 0.0 25 56.8 1 8.3 3 60.0 1 10.0  
Palpable splenomegaly
†
              
No 61 70.9 5 32.3 43 97.7 6 54.6 2 40.0 5 50.0 <0.001 
Yes 25 29.1 11 68.7 1 2.3 5 45.4 3 60.0 5 50.0  
Osteopenia
†
              
No 18 29.0 2 25.0 9 22.5 3 60.0 2 50.0 2 40.0 0.282 
Yes 44 71.0 6 75.0 31 77.5 2 40.0 2 50.0 3 60.0  
Osteoporosis
†
              
No 39 62.9 3 37.5 27 67.5 3 60.0 4 100.0 2 40.0 0.203 
Yes 23 37.1 5 62.5 13 32.5 2 40.0 0 0.0 3 60.0  
Serum ALP (U/L)
 †
              
≤ 104 39 61.9 3 25.0 28 82.3 4 66.7 1 25.0 3 42.9 0.001 
> 104 24 38.1 9 75.0 6 17.7 2 33.3 3 75.0 4 57.1  




186                                    ( 
46 - 712) 
338                
(113-564) 
182.5            
(90-384) 
149             
(117-290) 
125.5     (46-
189) 





3.4                              (0.5-
15.4) 
7.6                 (5.1-
9.4) 
2.5             (0.5-
15.2) 
1.6              (0.9-
2.4) 
8.2        (1.6-
15.4) 
3.2        
(2.7-5.8) 
 
Deaths 29 33.3 10 62.5 2 4.6 10 83.3 0 0.0 7 70.0 <0.001 
SETD2 protein levels: 
median (min-max) 
0.42                            (0.0-
1.0) 
0                   (0.0-
0.80) 
0.69           (0.0-
1.0) 
0                 (0.0-
0.76) 
0.24      (0.0-
0.86) 




levels: median (min-max) 
0.33                           (0.0-
1.12) 
0                   (0.0-
0.85) 
0.69           (0.0-
1.12) 
0                 (0.0-
1.0) 
0.17      (0.0-
0.67) 
0.16    
(0.0-0.79) 
<0.001 
Table 8. Comparison of the clinical characteristics of patients among WHO different subtypes 
 
5.2.2 SETD2 expression and H3K36Me value confirm their association with WHO subtype  
With our previous results (Leukemia, 2018) we had showed that MCL and ASM had significantly 
lower levels of SETD2 protein (p<0.001 and p=0.002, respectively) and H3K36Me3 (p<0.001 and p 
=0.004, respectively) as compared to ISM. The updated analysis carried out on an extended series, 
including a higher number of non-advanced forms, confirms those results. The distribution of 
SETD2 and H3K36Me3 values was quite different among the WHO subtypes (p<0.001 in both 
cases)(Figure 29). In particular the median SETD2 values were 0 (range 0.0-0.80) in ASMs, 0 (range 
0.00-0.76) in MCLs, and 0 (range 0.00-1.00) in SM-AHN 0.24 (range 0.0-0.86) in the SSMs, and 0.69 
(range 0.00-1.00) in the ISMs. Similar results were obtained for the H3K36Me3 values (p <0.001), 
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(Figure30) median of 0 (range 0.0-0.85) in the ASMs, 0 (range 0.0-1.0) in the MCLs, 0.16 (range 0.0-
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Figure 30. Boxplot of H3K36Me3 values distribution among the WHO subtypes 
 
5.2.3 Statistical correlation between SETD2 expression value and trimethylation  
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SETD2 is the only gene responsible for histone H3 trimethylation in Lisine 36, but the regulatory 
network controlling access to and modification of the H3K36 substrate remain complex and poorly 
understood, so we wondered if SETD2 expression and the related value of H3k36Me3 were two 
interchangeable measurements as they are thought to be. The correlation between SETD2 and 
trimethylation values was rather high (Pearson's coefficient of 0.897), although not perfect, 
meaning that there are probably many biological factors involved in the global process of DNA 
methylation in patients with mastocytosis, of any WHO subtype. 
 
 
Figure 31. Pearson’s correlation between SETD2 and trimethylation valuesin 88 patients 
 
5.2.4 Identification of a threshold of SETD2 expression and H3K36Me3 level than can identified 
Indolent Systemic mastocytosis 
In order to evaluate the diagnostic accuracy of SETD2 in distinguishing between forms of indolent 
mastocytosis, characterized by the absence of any sign of organ infiltration by the mast cells 
(absence of B-findings) from all others (thus also excluding the Smoldering forms), the ROC curve 
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was used. This analysis together with the use of some statistical methods, among which the 
Youden index, allowed to identify a cut-off for SETD2 corresponding to high levels of sensitivity 
and specificity. Through ROC curve analysis, we found that the SETD2 value of 0.425 discriminated 
ISM from other subtypes with a sensitivity of 84.09% and specificity of 86.36% (45 patients had a 
value <0.425, 43 patients ≥0.425). The area under the curve (AUC) was 0.87 (95% CI: 0.79-0.95). 
We also found that the H3K36Me3 value of 0.284 could discriminate quite well the two SM classes 
(ISM vs other subtypes). Associated sensitivity and specificity were of 86.36% and 79.55%, 
respectively (41 patients had a value <0.284, 47 patients ≥0.284). AUC was equal to 0.87 (95% CI: : 
0.79-0.95).  
 
5.2.5 Correlation between SETD2 expression, clinical phenotype and OS  
Overall, 29 deaths were observed in this study. The median follow-up, computed only on censored 




Figure 32. Kaplan–Meier estimates of OS of patients depending on WHO category in 88 
patients with SM 
 
The SETD2 expression assessed in terms of a binary variable using the ROC-based cut-off was 
significantly associated with OS (Figure 33). The same was observed for H3K36Me3 (Figure 34). For 
both markers, values above the cut-off were associated with longer OS. Median OS was  not 
reached (NR) in patients with SETD2 value ≥0.425 whereas was equals to 3.0 (1.37 – NR) for those 
with lower values. With regard to H3K36Me, median OS was not reached for patients with values 




Figure 33: Kaplan–Meier estimates of OS of patients depending on the SETD2 expression level 




Figure 34. Kaplan–Meier estimates of OS of patients depending on the H3K36Me3 value by 
WB in 88 patients with SM 
 
In ISM (n = 44, 50% of all patients), a SETD2 value <0.425 was observed in 7/44 patients (15.9%). In 
contrast, a SETD2 value ≥0.425 was present in 34/37 (91.9%) patients with AdvSM (ASM, ASM-
AHN, MCL, MCL-AHN). The comparison between a SETD2 value <0.425 and a SETD2 value ≥0.425 
revealed significant differences in almost all parameters, including age, Hb and Platelets level, 
serum alkaline phosphatase (ALP), serum tryptase and clinical parameters considered as the 
presence of skin lesions, severe anaphylaxis reactions, palpable splenomegaly (Table 8).  
 
Characteristics All patients SETD2 value  P H3k36me value P 
  







 n % n % n %  n % n %  
Gender             
F 42 47.7 26 57.8 16 37.2 0.053 23 56.1 19 40.4 0.142 
M 46 52.3 19 42.2 27 62.8  18 43.9 28 59.6  
 86 
Age (years): median (min-
max) 58 (19 – 78) 
63 (31-78) 52 (19-71) <0.001 63            (31-
78) 
53        (19-
75) 
0.024 
≤ 65 68 77.3 28 62.2 40 93.0 0.001 27 65.9 41 87.2 0.017 
> 65 20 22.7 17 37.8 3 7.0  14 34.2 6 12.8  
Hemoglobin (g/dl): median 
(min-max)
†
 13.4 (6.7 – 17.5) 
11.6                  (6.7-
15.9) 
14.4        
(9.3-17.5) 
<0.001 12           (6.7-
14.8) 
14.6        
(7.9-17.5) 
<0.001 
≥ 10 70 80.5 28 63.6 42 97.7 <0.001 26 65.0 44 93.6 0.001 
< 10 17 19.5 16 36.4 1 2.3  14 35.0 3 6.4  





        6.2 (1.9 – 76.0) 
7.0                    (1.9-
63.9) 
5.8       
(3.0-76.0) 
0.306 6.6          (1.9-
63.9) 
6               
(3-76) 
0.586 





 227.0 (13.0 – 979.0) 
191                    (13-
470) 
248    (113-
979) 
0.001 191           
(19-470) 
242       
(13-979) 
0.006 
≥ 100 70 80.5 27 61.4 43 100.0 <0.001 26 65.0 44 93.6 0.001 
< 100 17 19.5 17 38.6 0 0.0  14 35.0 3 6.4  
Serum tryptase (ug/L): 
median (min-max)
†
 52 (4.7 – 2250.0) 
        171               
(18.8-2250.0) 
25.3         
(52-4.7) 
<0.001 152         (7.6-
2250) 
30.3         
(4.7-2000) 
<0.001 
≤ 200 68 78.2 26 59.1 42 97.7 <0.001 25 62.5 43 91.5 0.002 
> 200 19 21.8 18 40.9 1 2.3  15 37.5 4 8.5  
Serum tryptase (ug/L)
†
             
< 20 18 20.7 1 2.27 17 39.5 <0.001 2 5.0 16 34.0 0.001 
≥ 20 69 79.3 43 97.7 26 60.5  38 95.0 31 66.0  
Skin lesions             
No 45 51.1 31 68.9 14 32.6 0.001 29 70.7 16 34.0 0.001 
Yes 43 48.9 14 31.1 29 67.4  12 29.3 31 66.0  
Mast cell mediator 
symptoms   
          
No 33 37.5 14 31.1 19 44.2 0.205 13 31.7 20 42.6 0.294 
Yes 55 62.5 31 68.9 24 55.8  28 68.3 27 57.5  
Severe anaphylaxis 
reactions   
          
No 58 65.9 38 84.4 20 46.5 <0.001 37 90.2 21 44.7 <0.001 
Yes 30 34.1 7 15.6 23 53.5  4 9.8 26 55.3  
Palpable splenomegaly
†
             
No 61 70.9 23 53.5 38 88.4 <0.001 21 53.9 40 85.1 0.001 
Yes 25 29.1 20 46.5 5 11.6  18 46.2 7 14.9  
Osteopenia
†
             
No 18 29.0 7 28.0 11 29.7 0.883 8 38.1 10 24.4 0.261 
Yes 44 71.0 18 72.0 26 70.3  13 61.9 31 75.6  
Osteoporosis
†
             
No 39 62.9 15 60.0 24 64.9 0.697 13 61.9 26 63.4 0.907 
Yes 23 37.1 10 40.0 13 35.1  8 38.1 15 36.6  
Serum ALP (U/L)
 †
             
≤ 104 39 61.9 11 37.93 28 82.4 <0.001 5 21.7 34 85.0 <0.001 
> 104 24 38.1 18 62.1 6 17.6  18 78.3 6 15.0  
Serum LDH (U/L): median 
(min-max)
†
 186 (46 - 712) 
186                    (46-
712) 
186       
(90-395) 
0.616 186          (46-
712) 
186      (90-
576) 
0.834 
Follow-up (years): median 
(min-max) 3.4 (0.5-15.4) 
5.6                    (0.9-
15.4) 
2.0       
(0.5-15.2) 
 6.1          (0.9-
15.4) 
2.0       
(0.5-15.2) 
 
Deaths 29 33.3 25 56.8 4 9.3  23 57.5 6 12.8  
 
Table 8. Comparison of the clinical characteristics of patients with a SETD2 value <0.425 and a 
SETD2 value ≥0.425 and with a H3K36Me3 value <0.284 and a H3K36Me3 value ≥0.284. 
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The results of univariate analyses for multiple clinical and laboratory variables concerning OS were 
reported in table 10: age ≥65 years (HR 4.1 (1.9-9.0), P= 0.0002), hemoglobin < 10 g/dl, HR 5.52 
(2.65-11.52), p<0.001, platelets < 100 × 109/L, HR 10.35 (4.91-21.75), P<0.001), markedly elevated 
serum tryptase (>200 μg/L, HR 3.6 (1.71–7.59), P = 0.001), palpable splenomegaly , HR 4 (1.87-
8.57), P<0.001), high SETD2 value (≥0.425, HR 0.14 (0.05-0.40), P<0.001), and high value of 
H3K36Me3 (≥ 0.284, HR 0.20 (0.08-0.49).  
 
Variables HR 95% CI P-value 
Sex    
F 1   
M 0.70 0.34-1.47 0.356 
Diagnosis  Diagnosis  
Others 1   
ISM 0.08 0.02-0.26 <0.001 
Presence of Skin Lesions    
No 1   
Yes 0.20 0.08-0.50 0.001 
Severe anaphylaxis reactions    
No 1   
Yes 0.17 0.05-0.56 0.004 
Presence of Mediator Related Symphtoms    
No 1   
Yes 1.89 0.081-4.42 0.143 
Osteopenia    
No 1   
Yes 0.55 0.18-1.69 0.299 
Osteoporosis    
No 1   
Yes 2.63 0.86-8.06 0.089 
Splenomegaly    
No 1   
Yes 4.00 1.87-8.57 <0.001 
Hb value (g/dL)    
≥ 10 1   
< 10 5.52 2.65-11.52 <0.001 
Platelet value (x 10
3
)    
≥ 100 1   
< 100 10.35 4.91-21.75 <0.001 
Serum Alkaline Phosphatase    
< 150  1   
≥ 150 2.22 0.86-5.73 0.101 
Serum tryptase level (ug/L)    
< 200 1   
≥ 200 3.60 1.71-7.59 0.001 
SETD2 level    
<  0.425 1   
≥ 0.425 0.14 0.05-0.40 <0.001 
H3K36Me3 level    
< 0.284 1   
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≥ 0.284 0.22 0.10-0.47 <0.001 
Continuous variables    
Age 1.37 1.16-1.66 <0.001 
Serum tryptase level 1.11 1.06-1.17 <0.001 
Hemoglobin 0.58 0.48-0.70 <0.001 
Platelets 0.43 0.29-0.67 <0.001 
White blood cells 1.18 0.96-1.44 0.112 
Eosinophils 1.51 1.09-2.08 0.012 
Lactate 2.66 1.87-3.77 <0.001 
Alkaline phosphatase 1.00 1.00-1.00 0.007 
SETD2 0.06 0.01-0.25 <0.001 
H3K36Me3 0.06 0.01-0.26 <0.001 
 
Table 9. Results of univariate analyses for multiple clinical and laboratory variables (Cox model) 
 
The heat map reported in Figure 35 shows the tetrachoric correlation among the variables 
included in this study (all considered as binary) as well as the diagnostic category (ISM vs other 
class) defined by WHO criteria and the two categorized biomarkers, SETD2 ≥ 0.425 and H3K36Me3 
≥ 0.284.  
Diagnosis of ISM is inversely correlated quite importantly with age (0: ≤65.1:> 65), triptase (0: 
≤200.1:> 200), phosphatase (0: ≤150.1:> 150), platelets (0: ≥100, 1: <100), hemoglobin (0: ≥10, 1: 
<10), and splenomegaly (0: no, 1 : Yes). Patients with diagnosis of ISM are younger, have lower 
triptase, phosphatase, higher values for platelets and hemoglobin and have no splenomegaly. The 
same correlations are found considering a value of SETD2 ≥ 0.425 and H3K36Me3 ≥ 0.284 (even if 
with a slightly lower intensity). This is because the cut-off identified for SETD2 expression divides 
ISM patients fairly well from all others.  
 





Figure 35. The heat map displays correlations between two individual parameters. Colors were 
assigned on basis of the value of the correlation coefficient . For example, a strong positive 
correlation (the other variable has a tendency to increase, in red) was observed between platelet 
and hemoglobin while a strong negative correlation (the other variable has a tendency to decrease, 
in blue) was observed between  platelets/hemoglobin and SETD2 elevated value, or ISM diagnosis. 
Cells that tend to white imply the almost absence of correlation.   
 
Due to the substantial correlation between clinical and laboratory factors and the diagnostic 
variable (ISM vs other) and of the very high correlation of the diagnostic variable and the two 
biomarkers, the multivariable analysis showed that only the diagnostic class defined by who 
 90 
criteria predicted OS. This result was expected due to the correlation among the considered 
variables. The diagnostic classes per se contain/bring also the informative content of other clinical 




Systemic Mastocytosis (SM) is a myeloproliferative neoplasm that includes a heterogeneous 
spectrum of disease variants ranging from indolent forms having an almost normal life 
expectation, to aggressive forms with dismal outcome. The D816V activating KIT gene mutation, 
responsible for mast cell proliferation, represents a key diagnostic criterion and a pathogenetic 
hallmark of SM. However, the mutation is present in ≥90% of patients, therefore it cannot alone 
explain the phenotypical and clinical heterogeneity of the disease. Despite the (potentially) early 
acquisition of the KIT D816V mutation during ontogeny, the onset of clinical symptoms associated 
with advanced forms of SM often occurs at middle or late adulthood. Such observations suggest 
that continuous activation of the defective (i.e., D816V-mutated) SCF/KIT pathway in an early 
progenitor cell does not confer a malignant phenotype per se, whereas it might facilitate 
malignant transformation of the disease, either because of an increased susceptibility to acquire 
secondary “oncogenic” mutations and/or by cooperating with a particular (preexisting) genetic 
background. We here show for the first time that perturbation of the SETD2/H3K36Me3 axis can 
be detected in virtually all patients with advanced SM. We can speculate that SETD2 down 
modulation/absence and H3K36Me3 deficiency may cooperate with, and potentiate the effects of 
the constitutive activation of the KIT pathway to determine the phenotype of advanced SM.  
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The SETD2 tumor suppressor, which encodes the only histone methyltransferase able to catalyze 
the trimethylation of histone H3 at Lysine 36, is implicated in the pathogenesis of several solid 
tumors (clear cell renal carcinoma [ccRCC] in primis) and of some acute leukemias via a variety of 
mechanisms including transcriptional and splicing defects, unfaithful homologous recombination 
repair and p53 inactivation64,66 .  
In ccRCCs, SETD2 loss of function mainly results from large monoallelic deletions or CN-LOH at 
chromosome 3p followed by mutation of the remaining allele. In acute leukemias, it rather derives 
from biallelic missense or truncating mutations. In SM, inactivating (biallelic) mutations were found 
only in the index case. Anyway, reduced SETD2 protein expression to various extents was observed 
in all cases studied and, similarly to ccRCC, where lower SETD2 and H3K36Me3 levels as assessed 
by immunohistochemistry correlate with larger tumor burden, more advanced stage and worse 
prognosis86, we found that very low or absent protein expression especially marked the cases with 
advanced SM. As expected, this was mirrored by similarly reduced, or totally abrogated, 
H3K36Me3.  
We confirmed that SETD2 loss of function may play a pathogenetic role in SM. We observed that in 
SM, SETD2 loss of function correlates with increased DNA damage that might be responsible for 
the accumulation of additional molecular/cellular defects accounting for the phenotypic and 
clinical heterogeneity of the disease. Increased genetic instability may be result of the p53 
checkpoint disruption as a consequence of SETD2 loss as well as the result of impaired double 
strand break recognition by the homologous recombination machinery as a consequence of H3K36 
trimethylation deficiency. 
Trying to delineate the mechanisms underlying SETD2 loss of function in SM, we uncovered a 
previously unreported non-genomic mechanism based on hyperubiquitination and enhanced 
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proteasome-mediated degradation. Intriguingly, inhibition of proteasome-mediated degradation 
by bortezomib rescued not only SETD2 expression but also H3K36Me trimethylation, indicating 
that this novel mechanism is reversible and that SETD2 loss of function in advSM is druggable. 
When tested in vitro in cell lines and primary patient cells, bortezomib was found to be strikingly 
effective (at subnanomolar concentrations) in inducing apoptosis and reducing clonogenic growth 
of neoplastic MCs. The mechanism through which proteasome inhibitors induce apoptosis in our 
in vitro and ex vivo models may involve an increase in levels of tumor suppressor SETD2, able to 
stabilize and activate p53 and a consequent increase in cell cycle regulators p27, p21 and gadd45a, 
as well as an increase in pro-apoptotic protein Bax. We further investigated the events upstream 
SETD2 hyperubiquitination in an attempt to find other druggable vulnerabilities, and identified 
two attractive targets: MDM2 and Aurora kinase A (AKA).  The MDM2 oncogene is amplified and 
overexpressed in a number of human malignancies and encodes an E3 ubiquitin ligase known to 
be a negative regulator of the tumour suppressor p53. Based on the observation that SETD2 may 
interact with p53 in neoplastic MCs (similarly to what has been reported in ccRCCs)85, we 
hypothesized that MDM2 may also target SETD2. Looking for the phosphorylation event capable 
to trigger SETD2 ubiquitination by MDM2, we focused our attention on AKA since it emerged from 
public databases of protein-protein interactions when we searched for SETD2-interacting kinases. 
AKA is a serine/threonine kinase that has been implicated in the regulation of mitosis and 
identified as a potential target in solid tumors and leukemias87. The AKA-targeting drug danusertib 
induces cell cycle arrest and apoptosis in various neoplastic cells.  Here, we show for the first time 
that neoplastic MCs display overexpression and hyper-activation of AKA leading to an hyper-
phosphorylation of SETD2 and a consequent hyper-ubiquitination by MDM2, driving SETD2 
proteasomal degradation. Danusertib treatment rescued SETD2 expression and activity and 
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induced apoptosis in a dose-dependent manner and reduced clonogenic potential in neoplastic 
MCs. In contrast, MDM2 inhibition rescued SETD2 expression and activity but showed only 
cytostatic and not cytotoxic effects. Our findings open new therapeutic avenues in advSM. 
Cladribine, interferon, or the recently approved KIT inhibitor midostaurin are currently the main 
options for advanced SM patients, and hematopoietic stem cell transplant is also considered in 
younger patients. However, in many cases with advanced SM intensive therapy cannot be applied 
because of age or poor performance status. In addition, many patients relapse on therapy or have 
resistant disease to midostaurin. Thus, biomarkers of response to midostaurin, as well as other 
treatment options, are urgently needed. We found that by partially inhibiting AKA, midostaurin 
may increase SETD2 and H3K36 trimethylation levels. Our preliminary observations, worth testing 
in larger series of patients, indicate that SETD2 re-expression can be observed in patients who 
respond to midostaurin as early as after 3 months of treatment, whereas refractory patients do 
not show any significant increase in SETD2 levels. As far as alternative treatment options targeting 
the AKA/MDM2/proteasome axis, we focused on testing drugs (like bortezomib and danusertib) 
already approved or in advanced clinical development for other conditions, aware that 
repurposing of an existing drug may be much easier and faster than testing novel compounds 
starting from phase I trials, especially in a rare disease like SM.  
In an initial cohort of SM patients (Leukemia, 2018) we had shown that MCL and ASM had 
significantly lower levels of SETD2 protein (p<0.001 and p=0.002, respectively) and H3K36Me3 
(p<0.001 and p =0.004, respectively) as compared to ISM and SSM. The updated analysis carried 
out on an extended series, including a higher number of non-advanced forms, confirms those 
results. The statistical difference in levels (p<0.001) between each form is highly significant, and 
confirms the different clinical behavior of WHO subtypes (Figure 29). In particular, median SETD2 
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values were 0 (range, 0.00-0.76) in MCLs, 0 (range, 0.0-0.80) in ASMs, 0 (range, 0.00-1.00) in SM-
AHN, 0.24 (range, 0.0-0.86) in SSMs, and 0.69 (range, 0.00-1.00) in ISMs. In the group of SM-AHN, 
SETD2 and H3K36Me3 values varied greatly. Nowadays the subset of SM-AHN is of particular 
interest, for their variable OS and for the detection of myeloid additional mutations in a large 
proportion of them35,36. Screening for additional ‘myeloid’ gene mutations (e.g., ASXL1, SRSF2, 
RUNX1, etc), performed on this group, showed some insights but they were not conclusive and no 
specific association of molecular alterations was identified27,28. In the future, further analysis of 
SETD2/H3K36 trimethylation levels, presence of specific additional myeloid mutations and 
outcome in a larger series of SM-AHN patients is warranted. 
In order to evaluate the diagnostic accuracy of SETD2 in distinguishing between different clinical 
forms of SM, we tried to obtain the best ROC curve grouping the different subtypes. Indolent 
mastocytosis, characterized by the absence of any sign of organ infiltration by neoplastic MCs 
(absence of B-findings) were distiguished with great precision from all others (including the 
smoldering forms): a SETD2 value of 0.425 discriminated ISM from all other WHO subtypes with a 
sensitivity of 84.09% and a specificity of 86.36% (45 patients had a value <0.425, 43 patients 
≥0.425). The area under the curve (AUC) was 0.87 (95% CI: 0.79-0.95). We also found that the 
H3K36Me3 value of 0.284 could discriminate quite well ISM from other subtypes. The impact of 
this observation is very important for the clinical practice, for example in the first approach to very 
symptomatic patients who can mimick an aggressive form for the presence of mediator-related 
symptoms, or to characterize the SM component in a case of SM-AHN. One of the major concerns 
about the clinical approach to SM-AHN is the choice of therapy, that depends on understanding 
which of the two pathologies is the most symptomatic for the patient. In this regard, we believe 
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that the evaluation of SETD2/H3K36Me3 status has the potential to become an important 
prognostic factor when assessed in larger series of SM-AHN.  
On the basis of univariate analysis, we demonstrated that low SETD2 and H3K36Me3 values are 
strong adverse prognostic parameters for OS (Figure 33 and 34) in patient with SM. The close 
correspondence between this biological parameter and the clinical factors that are recognized as 
independent factors in the main survival scores recently validated in large series of patients (such 
as Hb level, platelet value and splenomegaly), makes it very intriguing. The presence of additional 
myeloid mutations has a prognostic value in the setting of AdvSMs, and recent data suggest that 
they might also influence the risk of progression of ISM, but the scenario is still complex and a 
possible role for SETD2/H3K36 trimethylation deficiency will have to be assessed.  
A last consideration concerns the rare cases of MCL, that is considered the most aggressive 
subtype of SM. The KIT mutational status of a large cohort of patients with AdvSM was recently 
revised, and it has to be emphasized that 5-7% of patients tested negative for mutation of the KIT 
gene, in particular among MCL cases (8/31)27. In the same study, more than one third of patients 
who were wild-type for KIT mutation (37%) did not have any other detectable mutation, and this 
underlines the importance of the evaluation of SETD2 expression as a prognostic factor. MCL 
accounted for 17% of patients in our cohort, and, as reported in literature, they were largely 
negative for the KIT D16V mutation (4/15 tested negative when a highly sensitive digital PCR assay 
was used).  
In conclusion, we show that non-genomic loss-of-function of SETD2 is a recurrent event in 
advanced SM. SETD2 and H3K36Me3 deficiency might cooperate with the ligand-independent 
activation of the KIT pathway to enhance leukemic transformation and progression and determine 
the phenotype of ASM and MCL. Targeting SETD2 down-modulation itself (with bortezomib or 
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second-generation proteasome inhibitors) and/or SETD2/KIT cooperation are promising 
therapeutic strategies to improve the outcome of AdvSM. SETD2/H3K36 trimethylation deficiency 
seems to be a prognostic factor predicting for poor OS and has the potential to be a biomarker of 
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